AU670069B2 – Chemical compounds
– Google Patents
AU670069B2 – Chemical compounds
– Google Patents
Chemical compounds
Download PDF
Info
Publication number
AU670069B2
AU670069B2
AU36423/93A
AU3642393A
AU670069B2
AU 670069 B2
AU670069 B2
AU 670069B2
AU 36423/93 A
AU36423/93 A
AU 36423/93A
AU 3642393 A
AU3642393 A
AU 3642393A
AU 670069 B2
AU670069 B2
AU 670069B2
Authority
AU
Australia
Prior art keywords
polymers
polymer
groups
pct
carbonate
Prior art date
1992-03-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU36423/93A
Other versions
AU3642393A
(en
Inventor
Jo Klaveness
Keith Redford
Jan Solberg
Per Strande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1992-03-06
Filing date
1993-03-05
Publication date
1996-07-04
1993-03-05
Application filed by Nycomed Imaging AS
filed
Critical
Nycomed Imaging AS
1993-10-05
Publication of AU3642393A
publication
Critical
patent/AU3642393A/en
1996-07-04
Application granted
granted
Critical
1996-07-04
Publication of AU670069B2
publication
Critical
patent/AU670069B2/en
2013-03-05
Anticipated expiration
legal-status
Critical
Status
Ceased
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
150000001875
compounds
Chemical class
0.000
title
description
19
229920000642
polymer
Polymers
0.000
claims
abstract
description
143
125000004435
hydrogen atom
Chemical group
[H]*
0.000
claims
abstract
description
11
125000000962
organic group
Chemical group
0.000
claims
abstract
description
11
108090000765
processed proteins & peptides
Proteins
0.000
claims
abstract
description
10
229920003169
water-soluble polymer
Polymers
0.000
claims
abstract
description
10
229920001184
polypeptide
Polymers
0.000
claims
abstract
description
9
102000004196
processed proteins & peptides
Human genes
0.000
claims
abstract
description
9
-1
oxy, carbonyl
Chemical group
0.000
claims
description
38
238000000034
method
Methods
0.000
claims
description
20
150000003254
radicals
Chemical class
0.000
claims
description
19
238000006243
chemical reaction
Methods
0.000
claims
description
17
125000004432
carbon atom
Chemical group
C*
0.000
claims
description
16
239000000178
monomer
Substances
0.000
claims
description
12
125000000217
alkyl group
Chemical group
0.000
claims
description
9
125000005842
heteroatom
Chemical group
0.000
claims
description
9
IJGRMHOSHXDMSA-UHFFFAOYSA-N
Atomic nitrogen
Chemical group
N#N
IJGRMHOSHXDMSA-UHFFFAOYSA-N
0.000
claims
description
8
239000003153
chemical reaction reagent
Substances
0.000
claims
description
8
230000003111
delayed effect
Effects
0.000
claims
description
7
230000008569
process
Effects
0.000
claims
description
7
125000003118
aryl group
Chemical group
0.000
claims
description
6
125000005647
linker group
Chemical group
0.000
claims
description
6
239000000203
mixture
Substances
0.000
claims
description
6
229910052757
nitrogen
Inorganic materials
0.000
claims
description
6
ZLMJMSJWJFRBEC-UHFFFAOYSA-N
Potassium
Chemical compound
[K]
ZLMJMSJWJFRBEC-UHFFFAOYSA-N
0.000
claims
description
5
239000005864
Sulphur
Chemical group
0.000
claims
description
5
239000003814
drug
Substances
0.000
claims
description
5
229940079593
drug
Drugs
0.000
claims
description
5
150000004676
glycans
Chemical class
0.000
claims
description
5
125000000623
heterocyclic group
Chemical group
0.000
claims
description
5
229920001282
polysaccharide
Polymers
0.000
claims
description
5
239000005017
polysaccharide
Substances
0.000
claims
description
5
229910052700
potassium
Inorganic materials
0.000
claims
description
5
239000011591
potassium
Substances
0.000
claims
description
5
239000004372
Polyvinyl alcohol
Substances
0.000
claims
description
4
NINIDFKCEFEMDL-UHFFFAOYSA-N
Sulfur
Chemical group
[S]
NINIDFKCEFEMDL-UHFFFAOYSA-N
0.000
claims
description
4
125000001931
aliphatic group
Chemical group
0.000
claims
description
4
QVGXLLKOCUKJST-UHFFFAOYSA-N
atomic oxygen
Chemical group
[O]
QVGXLLKOCUKJST-UHFFFAOYSA-N
0.000
claims
description
4
229910052739
hydrogen
Inorganic materials
0.000
claims
description
4
125000001841
imino group
Chemical group
[H]N=*
0.000
claims
description
4
239000007943
implant
Substances
0.000
claims
description
4
239000001301
oxygen
Substances
0.000
claims
description
4
229910052760
oxygen
Inorganic materials
0.000
claims
description
4
229920002451
polyvinyl alcohol
Polymers
0.000
claims
description
4
125000001424
substituent group
Chemical group
0.000
claims
description
4
239000004593
Epoxy
Substances
0.000
claims
description
3
229920002845
Poly(methacrylic acid)
Polymers
0.000
claims
description
3
239000004952
Polyamide
Substances
0.000
claims
description
3
229920002125
Sokalan®
Polymers
0.000
claims
description
3
125000002947
alkylene group
Chemical group
0.000
claims
description
3
229920006037
cross link polymer
Polymers
0.000
claims
description
3
238000009472
formulation
Methods
0.000
claims
description
3
239000001257
hydrogen
Substances
0.000
claims
description
3
125000005740
oxycarbonyl group
Chemical group
[*:1]OC([*:2])=O
0.000
claims
description
3
125000001997
phenyl group
Chemical group
[H]C1=C([H])C([H])=C(*)C([H])=C1[H]
0.000
claims
description
3
239000004014
plasticizer
Substances
0.000
claims
description
3
239000004584
polyacrylic acid
Substances
0.000
claims
description
3
229920002647
polyamide
Polymers
0.000
claims
description
3
229920000728
polyester
Polymers
0.000
claims
description
3
229920002635
polyurethane
Polymers
0.000
claims
description
3
239000004814
polyurethane
Substances
0.000
claims
description
3
QQONPFPTGQHPMA-UHFFFAOYSA-N
propylene
Chemical group
CC=C
QQONPFPTGQHPMA-UHFFFAOYSA-N
0.000
claims
description
3
125000004805
propylene group
Chemical group
[H]C([H])([H])C([H])([*:1])C([H])([H])[*:2]
0.000
claims
description
3
NIXOWILDQLNWCW-UHFFFAOYSA-M
Acrylate
Chemical compound
[O-]C(=O)C=C
NIXOWILDQLNWCW-UHFFFAOYSA-M
0.000
claims
description
2
VGGSQFUCUMXWEO-UHFFFAOYSA-N
Ethene
Chemical group
C=C
VGGSQFUCUMXWEO-UHFFFAOYSA-N
0.000
claims
description
2
239000005977
Ethylene
Substances
0.000
claims
description
2
UFHFLCQGNIYNRP-UHFFFAOYSA-N
Hydrogen
Chemical compound
[H][H]
UFHFLCQGNIYNRP-UHFFFAOYSA-N
0.000
claims
description
2
CERQOIWHTDAKMF-UHFFFAOYSA-M
Methacrylate
Chemical compound
CC(=C)C([O-])=O
CERQOIWHTDAKMF-UHFFFAOYSA-M
0.000
claims
description
2
239000003905
agrochemical
Substances
0.000
claims
description
2
125000000753
cycloalkyl group
Chemical group
0.000
claims
description
2
229920000570
polyether
Polymers
0.000
claims
description
2
210000004872
soft tissue
Anatomy
0.000
claims
description
2
239000004721
Polyphenylene oxide
Substances
0.000
claims
1
239000012216
imaging agent
Substances
0.000
claims
1
125000001570
methylene group
Chemical group
[H]C([H])([*:1])[*:2]
0.000
claims
1
OKKJLVBELUTLKV-UHFFFAOYSA-N
Methanol
Chemical compound
OC
OKKJLVBELUTLKV-UHFFFAOYSA-N
0.000
description
63
239000000243
solution
Substances
0.000
description
59
WYURNTSHIVDZCO-UHFFFAOYSA-N
Tetrahydrofuran
Chemical compound
C1CCOC1
WYURNTSHIVDZCO-UHFFFAOYSA-N
0.000
description
50
239000002904
solvent
Substances
0.000
description
46
ZMXDDKWLCZADIW-UHFFFAOYSA-N
N,N-Dimethylformamide
Chemical compound
CN(C)C=O
ZMXDDKWLCZADIW-UHFFFAOYSA-N
0.000
description
42
239000011541
reaction mixture
Substances
0.000
description
40
238000005481
NMR spectroscopy
Methods
0.000
description
38
XLYOFNOQVPJJNP-UHFFFAOYSA-N
water
Substances
O
XLYOFNOQVPJJNP-UHFFFAOYSA-N
0.000
description
35
YMWUJEATGCHHMB-UHFFFAOYSA-N
Dichloromethane
Chemical compound
ClCCl
YMWUJEATGCHHMB-UHFFFAOYSA-N
0.000
description
33
238000001542
size-exclusion chromatography
Methods
0.000
description
33
HEDRZPFGACZZDS-UHFFFAOYSA-N
Chloroform
Chemical compound
ClC(Cl)Cl
HEDRZPFGACZZDS-UHFFFAOYSA-N
0.000
description
29
239000000047
product
Substances
0.000
description
29
BVKZGUZCCUSVTD-UHFFFAOYSA-L
Carbonate
Chemical compound
[O-]C([O-])=O
BVKZGUZCCUSVTD-UHFFFAOYSA-L
0.000
description
26
OZAIFHULBGXAKX-UHFFFAOYSA-N
2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile
Chemical compound
N#CC(C)(C)N=NC(C)(C)C#N
OZAIFHULBGXAKX-UHFFFAOYSA-N
0.000
description
20
JUJWROOIHBZHMG-UHFFFAOYSA-N
Pyridine
Chemical compound
C1=CC=NC=C1
JUJWROOIHBZHMG-UHFFFAOYSA-N
0.000
description
20
238000003818
flash chromatography
Methods
0.000
description
19
OZAIFHULBGXAKX-VAWYXSNFSA-N
AIBN
Substances
N#CC(C)(C)\N=N\C(C)(C)C#N
OZAIFHULBGXAKX-VAWYXSNFSA-N
0.000
description
18
HEMHJVSKTPXQMS-UHFFFAOYSA-M
Sodium hydroxide
Chemical compound
[OH-].[Na+]
HEMHJVSKTPXQMS-UHFFFAOYSA-M
0.000
description
18
UIIMBOGNXHQVGW-UHFFFAOYSA-M
Sodium bicarbonate
Chemical class
[Na+].OC([O-])=O
UIIMBOGNXHQVGW-UHFFFAOYSA-M
0.000
description
17
238000003756
stirring
Methods
0.000
description
16
XEZNGIUYQVAUSS-UHFFFAOYSA-N
18-crown-6
Chemical compound
C1COCCOCCOCCOCCOCCO1
XEZNGIUYQVAUSS-UHFFFAOYSA-N
0.000
description
13
XEKOWRVHYACXOJ-UHFFFAOYSA-N
Ethyl acetate
Chemical compound
CCOC(C)=O
XEKOWRVHYACXOJ-UHFFFAOYSA-N
0.000
description
12
VLKZOEOYAKHREP-UHFFFAOYSA-N
n-Hexane
Chemical compound
CCCCCC
VLKZOEOYAKHREP-UHFFFAOYSA-N
0.000
description
12
125000003178
carboxy group
Chemical group
[H]OC(*)=O
0.000
description
11
125000001495
ethyl group
Chemical group
[H]C([H])([H])C([H])([H])*
0.000
description
11
239000012299
nitrogen atmosphere
Substances
0.000
description
11
239000002245
particle
Substances
0.000
description
11
VEXZGXHMUGYJMC-UHFFFAOYSA-N
Hydrochloric acid
Chemical compound
Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-N
0.000
description
10
239000000843
powder
Substances
0.000
description
10
UMJSCPRVCHMLSP-UHFFFAOYSA-N
pyridine
Natural products
COC1=CC=CN=C1
UMJSCPRVCHMLSP-UHFFFAOYSA-N
0.000
description
10
CERQOIWHTDAKMF-UHFFFAOYSA-N
Methacrylic acid
Chemical compound
CC(=C)C(O)=O
CERQOIWHTDAKMF-UHFFFAOYSA-N
0.000
description
9
239000002253
acid
Substances
0.000
description
9
238000000113
differential scanning calorimetry
Methods
0.000
description
9
239000000839
emulsion
Substances
0.000
description
9
239000012074
organic phase
Substances
0.000
description
9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N
Silicium dioxide
Chemical compound
O=[Si]=O
VYPSYNLAJGMNEJ-UHFFFAOYSA-N
0.000
description
8
229920002988
biodegradable polymer
Polymers
0.000
description
8
239000004621
biodegradable polymer
Substances
0.000
description
8
230000015572
biosynthetic process
Effects
0.000
description
8
238000001035
drying
Methods
0.000
description
8
239000000741
silica gel
Substances
0.000
description
8
229910002027
silica gel
Inorganic materials
0.000
description
8
229960001866
silicon dioxide
Drugs
0.000
description
8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
Ethanol
Chemical compound
CCO
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
0.000
description
7
238000006065
biodegradation reaction
Methods
0.000
description
7
239000007857
degradation product
Substances
0.000
description
7
125000002496
methyl group
Chemical group
[H]C([H])([H])*
0.000
description
7
229920006395
saturated elastomer
Polymers
0.000
description
7
239000000725
suspension
Substances
0.000
description
7
QTBSBXVTEAMEQO-UHFFFAOYSA-N
Acetic acid
Chemical compound
CC(O)=O
QTBSBXVTEAMEQO-UHFFFAOYSA-N
0.000
description
6
XKYNLGVLGFPYRQ-UHFFFAOYSA-N
butoxycarbonyloxymethyl 2-methylprop-2-enoate
Chemical compound
CCCCOC(=O)OCOC(=O)C(C)=C
XKYNLGVLGFPYRQ-UHFFFAOYSA-N
0.000
description
6
230000009477
glass transition
Effects
0.000
description
6
230000007062
hydrolysis
Effects
0.000
description
6
238000006460
hydrolysis reaction
Methods
0.000
description
6
239000000463
material
Substances
0.000
description
6
FQPSGWSUVKBHSU-UHFFFAOYSA-N
methacrylamide
Chemical class
CC(=C)C(N)=O
FQPSGWSUVKBHSU-UHFFFAOYSA-N
0.000
description
6
235000017557
sodium bicarbonate
Nutrition
0.000
description
6
229910000030
sodium bicarbonate
Inorganic materials
0.000
description
6
108090000371
Esterases
Proteins
0.000
description
5
238000004458
analytical method
Methods
0.000
description
5
230000015556
catabolic process
Effects
0.000
description
5
230000003197
catalytic effect
Effects
0.000
description
5
239000003795
chemical substances by application
Substances
0.000
description
5
238000003776
cleavage reaction
Methods
0.000
description
5
238000000354
decomposition reaction
Methods
0.000
description
5
238000006731
degradation reaction
Methods
0.000
description
5
125000002887
hydroxy group
Chemical group
[H]O*
0.000
description
5
230000007017
scission
Effects
0.000
description
5
GQHTUMJGOHRCHB-UHFFFAOYSA-N
2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine
Chemical compound
C1CCCCN2CCCN=C21
GQHTUMJGOHRCHB-UHFFFAOYSA-N
0.000
description
4
QTBSBXVTEAMEQO-UHFFFAOYSA-M
Acetate
Chemical compound
CC([O-])=O
QTBSBXVTEAMEQO-UHFFFAOYSA-M
0.000
description
4
CURLTUGMZLYLDI-UHFFFAOYSA-N
Carbon dioxide
Chemical compound
O=C=O
CURLTUGMZLYLDI-UHFFFAOYSA-N
0.000
description
4
239000004159
Potassium persulphate
Substances
0.000
description
4
239000000460
chlorine
Substances
0.000
description
4
239000012043
crude product
Substances
0.000
description
4
125000003700
epoxy group
Chemical group
0.000
description
4
150000002148
esters
Chemical class
0.000
description
4
MKEVFCHVGWJVEU-UHFFFAOYSA-N
ethoxycarbonyloxymethyl 2-methylprop-2-enoate
Chemical compound
CCOC(=O)OCOC(=O)C(C)=C
MKEVFCHVGWJVEU-UHFFFAOYSA-N
0.000
description
4
238000001914
filtration
Methods
0.000
description
4
125000000524
functional group
Chemical group
0.000
description
4
125000000325
methylidene group
Chemical group
[H]C([H])=*
0.000
description
4
USHAGKDGDHPEEY-UHFFFAOYSA-L
potassium persulfate
Chemical compound
[K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O
USHAGKDGDHPEEY-UHFFFAOYSA-L
0.000
description
4
235000019394
potassium persulphate
Nutrition
0.000
description
4
239000000126
substance
Substances
0.000
description
4
WAIFIHKBNYUZGZ-UHFFFAOYSA-N
1-(2-methylprop-2-enoylamino)propan-2-yloxycarbonyloxymethyl acetate
Chemical compound
CC(=C)C(=O)NCC(C)OC(=O)OCOC(C)=O
WAIFIHKBNYUZGZ-UHFFFAOYSA-N
0.000
description
3
UUFQTNFCRMXOAE-UHFFFAOYSA-N
1-methylmethylene
Chemical compound
C[CH]
UUFQTNFCRMXOAE-UHFFFAOYSA-N
0.000
description
3
JTAMKVMVSJVIKP-UHFFFAOYSA-N
2-chloroethyl methyl carbonate
Chemical compound
COC(=O)OCCCl
JTAMKVMVSJVIKP-UHFFFAOYSA-N
0.000
description
3
GKNFVGPGMZRWDQ-UHFFFAOYSA-N
2-methylprop-2-enoyloxymethyl morpholine-4-carboxylate
Chemical compound
CC(=C)C(=O)OCOC(=O)N1CCOCC1
GKNFVGPGMZRWDQ-UHFFFAOYSA-N
0.000
description
3
KXDHJXZQYSOELW-UHFFFAOYSA-M
Carbamate
Chemical compound
NC([O-])=O
KXDHJXZQYSOELW-UHFFFAOYSA-M
0.000
description
3
108090000790
Enzymes
Proteins
0.000
description
3
102000004190
Enzymes
Human genes
0.000
description
3
229920003171
Poly (ethylene oxide)
Polymers
0.000
description
3
DBMJMQXJHONAFJ-UHFFFAOYSA-M
Sodium laurylsulphate
Chemical compound
[Na+].CCCCCCCCCCCCOS([O-])(=O)=O
DBMJMQXJHONAFJ-UHFFFAOYSA-M
0.000
description
3
150000007513
acids
Chemical class
0.000
description
3
150000001299
aldehydes
Chemical class
0.000
description
3
239000002585
base
Substances
0.000
description
3
125000001797
benzyl group
Chemical group
[H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])*
0.000
description
3
MBUCWFHXWNITCQ-UHFFFAOYSA-N
butyl chloromethyl carbonate
Chemical compound
CCCCOC(=O)OCCl
MBUCWFHXWNITCQ-UHFFFAOYSA-N
0.000
description
3
QVISUHUAVCZFMP-UHFFFAOYSA-N
carboxyoxymethyl 2-methylprop-2-enoate
Chemical compound
CC(=C)C(=O)OCOC(O)=O
QVISUHUAVCZFMP-UHFFFAOYSA-N
0.000
description
3
239000002738
chelating agent
Substances
0.000
description
3
239000002872
contrast media
Substances
0.000
description
3
238000004132
cross linking
Methods
0.000
description
3
238000012377
drug delivery
Methods
0.000
description
3
125000005843
halogen group
Chemical group
0.000
description
3
125000001183
hydrocarbyl group
Chemical group
0.000
description
3
239000003999
initiator
Substances
0.000
description
3
229910052740
iodine
Inorganic materials
0.000
description
3
150000002576
ketones
Chemical class
0.000
description
3
239000003960
organic solvent
Substances
0.000
description
3
230000005298
paramagnetic effect
Effects
0.000
description
3
TVDCUCKBZCDWRS-UHFFFAOYSA-N
phenylmethoxycarbonyloxymethyl 2-methylprop-2-enoate
Chemical compound
CC(=C)C(=O)OCOC(=O)OCC1=CC=CC=C1
TVDCUCKBZCDWRS-UHFFFAOYSA-N
0.000
description
3
XAEFZNCEHLXOMS-UHFFFAOYSA-M
potassium benzoate
Chemical compound
[K+].[O-]C(=O)C1=CC=CC=C1
XAEFZNCEHLXOMS-UHFFFAOYSA-M
0.000
description
3
LPNYRYFBWFDTMA-UHFFFAOYSA-N
potassium tert-butoxide
Chemical compound
[K+].CC(C)(C)[O-]
LPNYRYFBWFDTMA-UHFFFAOYSA-N
0.000
description
3
LLLCSBYSPJHDJX-UHFFFAOYSA-M
potassium;2-methylprop-2-enoate
Chemical compound
[K+].CC(=C)C([O-])=O
LLLCSBYSPJHDJX-UHFFFAOYSA-M
0.000
description
3
125000002924
primary amino group
Chemical group
[H]N([H])*
0.000
description
3
235000019333
sodium laurylsulphate
Nutrition
0.000
description
3
229910052717
sulfur
Inorganic materials
0.000
description
3
238000003786
synthesis reaction
Methods
0.000
description
3
YLQBMQCUIZJEEH-UHFFFAOYSA-N
tetrahydrofuran
Natural products
C=1C=COC=1
YLQBMQCUIZJEEH-UHFFFAOYSA-N
0.000
description
3
NIXOWILDQLNWCW-UHFFFAOYSA-N
2-Propenoic acid
Natural products
OC(=O)C=C
NIXOWILDQLNWCW-UHFFFAOYSA-N
0.000
description
2
VHYFNPMBLIVWCW-UHFFFAOYSA-N
4-Dimethylaminopyridine
Chemical compound
CN(C)C1=CC=NC=C1
VHYFNPMBLIVWCW-UHFFFAOYSA-N
0.000
description
2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N
7553-56-2
Chemical compound
[I]
ZCYVEMRRCGMTRW-UHFFFAOYSA-N
0.000
description
2
HRPVXLWXLXDGHG-UHFFFAOYSA-N
Acrylamide
Chemical compound
NC(=O)C=C
HRPVXLWXLXDGHG-UHFFFAOYSA-N
0.000
description
2
WKBOTKDWSSQWDR-UHFFFAOYSA-N
Bromine atom
Chemical compound
[Br]
WKBOTKDWSSQWDR-UHFFFAOYSA-N
0.000
description
2
VEXZGXHMUGYJMC-UHFFFAOYSA-M
Chloride anion
Chemical compound
[Cl-]
VEXZGXHMUGYJMC-UHFFFAOYSA-M
0.000
description
2
ZAMOUSCENKQFHK-UHFFFAOYSA-N
Chlorine atom
Chemical compound
[Cl]
ZAMOUSCENKQFHK-UHFFFAOYSA-N
0.000
description
2
XEEYBQQBJWHFJM-UHFFFAOYSA-N
Iron
Chemical compound
[Fe]
XEEYBQQBJWHFJM-UHFFFAOYSA-N
0.000
description
2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N
Iron oxide
Chemical compound
[Fe]=O
UQSXHKLRYXJYBZ-UHFFFAOYSA-N
0.000
description
2
CSNNHWWHGAXBCP-UHFFFAOYSA-L
Magnesium sulfate
Chemical compound
[Mg+2].[O-][S+2]([O-])([O-])[O-]
CSNNHWWHGAXBCP-UHFFFAOYSA-L
0.000
description
2
LRHPLDYGYMQRHN-UHFFFAOYSA-N
N-Butanol
Chemical compound
CCCCO
LRHPLDYGYMQRHN-UHFFFAOYSA-N
0.000
description
2
229920000954
Polyglycolide
Polymers
0.000
description
2
229920000331
Polyhydroxybutyrate
Polymers
0.000
description
2
229920001710
Polyorthoester
Polymers
0.000
description
2
FAPWRFPIFSIZLT-UHFFFAOYSA-M
Sodium chloride
Chemical compound
[Na+].[Cl-]
FAPWRFPIFSIZLT-UHFFFAOYSA-M
0.000
description
2
239000011149
active material
Substances
0.000
description
2
125000002252
acyl group
Chemical group
0.000
description
2
125000003342
alkenyl group
Chemical group
0.000
description
2
239000007864
aqueous solution
Substances
0.000
description
2
TZCXTZWJZNENPQ-UHFFFAOYSA-L
barium sulfate
Chemical compound
[Ba+2].[O-]S([O-])(=O)=O
TZCXTZWJZNENPQ-UHFFFAOYSA-L
0.000
description
2
HUMNYLRZRPPJDN-UHFFFAOYSA-N
benzaldehyde
Chemical compound
O=CC1=CC=CC=C1
HUMNYLRZRPPJDN-UHFFFAOYSA-N
0.000
description
2
229940050390
benzoate
Drugs
0.000
description
2
WPYMKLBDIGXBTP-UHFFFAOYSA-N
benzoic acid
Chemical compound
OC(=O)C1=CC=CC=C1
WPYMKLBDIGXBTP-UHFFFAOYSA-N
0.000
description
2
GDTBXPJZTBHREO-UHFFFAOYSA-N
bromine
Substances
BrBr
GDTBXPJZTBHREO-UHFFFAOYSA-N
0.000
description
2
229910052794
bromium
Inorganic materials
0.000
description
2
125000000484
butyl group
Chemical group
[H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H]
0.000
description
2
239000001569
carbon dioxide
Substances
0.000
description
2
229910002092
carbon dioxide
Inorganic materials
0.000
description
2
125000002915
carbonyl group
Chemical group
[*:2]C([*:1])=O
0.000
description
2
150000001732
carboxylic acid derivatives
Chemical class
0.000
description
2
239000000969
carrier
Substances
0.000
description
2
229910052801
chlorine
Inorganic materials
0.000
description
2
JYWJULGYGOLCGW-UHFFFAOYSA-N
chloromethyl chloroformate
Chemical compound
ClCOC(Cl)=O
JYWJULGYGOLCGW-UHFFFAOYSA-N
0.000
description
2
238000000576
coating method
Methods
0.000
description
2
238000009833
condensation
Methods
0.000
description
2
230000005494
condensation
Effects
0.000
description
2
238000007796
conventional method
Methods
0.000
description
2
238000001816
cooling
Methods
0.000
description
2
229920001577
copolymer
Polymers
0.000
description
2
150000003983
crown ethers
Chemical class
0.000
description
2
125000002704
decyl group
Chemical group
[H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])*
0.000
description
2
150000005690
diesters
Chemical group
0.000
description
2
238000004090
dissolution
Methods
0.000
description
2
238000001704
evaporation
Methods
0.000
description
2
230000008020
evaporation
Effects
0.000
description
2
230000005294
ferromagnetic effect
Effects
0.000
description
2
125000002485
formyl group
Chemical group
[H]C(*)=O
0.000
description
2
238000004108
freeze drying
Methods
0.000
description
2
239000007789
gas
Substances
0.000
description
2
238000001727
in vivo
Methods
0.000
description
2
239000011630
iodine
Substances
0.000
description
2
239000007788
liquid
Substances
0.000
description
2
210000004185
liver
Anatomy
0.000
description
2
238000004519
manufacturing process
Methods
0.000
description
2
229910021645
metal ion
Inorganic materials
0.000
description
2
125000005395
methacrylic acid group
Chemical group
0.000
description
2
231100000252
nontoxic
Toxicity
0.000
description
2
230000003000
nontoxic effect
Effects
0.000
description
2
239000005022
packaging material
Substances
0.000
description
2
229960005235
piperonyl butoxide
Drugs
0.000
description
2
239000005015
poly(hydroxybutyrate)
Substances
0.000
description
2
229920002401
polyacrylamide
Polymers
0.000
description
2
239000004633
polyglycolic acid
Substances
0.000
description
2
SCVFZCLFOSHCOH-UHFFFAOYSA-M
potassium acetate
Chemical compound
[K+].CC([O-])=O
SCVFZCLFOSHCOH-UHFFFAOYSA-M
0.000
description
2
239000004297
potassium metabisulphite
Substances
0.000
description
2
235000010263
potassium metabisulphite
Nutrition
0.000
description
2
QVOMDXSQDOBBMW-UHFFFAOYSA-L
potassium metabisulphite
Chemical compound
[K+].[K+].[O-]S(=O)OS([O-])=O
QVOMDXSQDOBBMW-UHFFFAOYSA-L
0.000
description
2
238000001556
precipitation
Methods
0.000
description
2
125000001436
propyl group
Chemical group
[H]C([*])([H])C([H])([H])C([H])([H])[H]
0.000
description
2
230000035484
reaction time
Effects
0.000
description
2
150000003839
salts
Chemical class
0.000
description
2
238000010561
standard procedure
Methods
0.000
description
2
239000007858
starting material
Substances
0.000
description
2
229920001169
thermoplastic
Polymers
0.000
description
2
239000004416
thermosoftening plastic
Substances
0.000
description
2
238000012546
transfer
Methods
0.000
description
2
XFNJVJPLKCPIBV-UHFFFAOYSA-N
trimethylenediamine
Chemical compound
NCCCN
XFNJVJPLKCPIBV-UHFFFAOYSA-N
0.000
description
2
125000000391
vinyl group
Chemical group
[H]C([*])=C([H])[H]
0.000
description
2
JIAARYAFYJHUJI-UHFFFAOYSA-L
zinc dichloride
Chemical compound
[Cl-].[Cl-].[Zn+2]
JIAARYAFYJHUJI-UHFFFAOYSA-L
0.000
description
2
WSLDOOZREJYCGB-UHFFFAOYSA-N
1,2-Dichloroethane
Chemical compound
ClCCCl
WSLDOOZREJYCGB-UHFFFAOYSA-N
0.000
description
1
VAYTZRYEBVHVLE-UHFFFAOYSA-N
1,3-dioxol-2-one
Chemical compound
O=C1OC=CO1
VAYTZRYEBVHVLE-UHFFFAOYSA-N
0.000
description
1
WZZBNLYBHUDSHF-DHLKQENFSA-N
1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone
Chemical compound
CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F
WZZBNLYBHUDSHF-DHLKQENFSA-N
0.000
description
1
YVRGKFXJZCTTRB-UHFFFAOYSA-N
1-chloroethyl ethyl carbonate
Chemical compound
CCOC(=O)OC(C)Cl
YVRGKFXJZCTTRB-UHFFFAOYSA-N
0.000
description
1
125000001478
1-chloroethyl group
Chemical group
[H]C([H])([H])C([H])(Cl)*
0.000
description
1
GALGFDDHBGDRFQ-UHFFFAOYSA-N
1-ethoxycarbonyloxyethyl 2-methylprop-2-enoate
Chemical compound
CCOC(=O)OC(C)OC(=O)C(C)=C
GALGFDDHBGDRFQ-UHFFFAOYSA-N
0.000
description
1
HRBNXCSWUDHDLM-UHFFFAOYSA-N
1-methoxycarbonyloxyethyl 2-methylprop-2-enoate
Chemical compound
COC(=O)OC(C)OC(=O)C(C)=C
HRBNXCSWUDHDLM-UHFFFAOYSA-N
0.000
description
1
238000001644
13C nuclear magnetic resonance spectroscopy
Methods
0.000
description
1
SMZOUWXMTYCWNB-UHFFFAOYSA-N
2-(2-methoxy-5-methylphenyl)ethanamine
Chemical compound
COC1=CC=C(C)C=C1CCN
SMZOUWXMTYCWNB-UHFFFAOYSA-N
0.000
description
1
ULIKDJVNUXNQHS-UHFFFAOYSA-N
2-Propene-1-thiol
Chemical compound
SCC=C
ULIKDJVNUXNQHS-UHFFFAOYSA-N
0.000
description
1
SVDDJQGVOFZBNX-UHFFFAOYSA-N
2-chloroethyl carbonochloridate
Chemical compound
ClCCOC(Cl)=O
SVDDJQGVOFZBNX-UHFFFAOYSA-N
0.000
description
1
SEEYHRCMNMPHDG-UHFFFAOYSA-N
2-chloroethyl ethyl carbonate
Chemical compound
CCOC(=O)OCCCl
SEEYHRCMNMPHDG-UHFFFAOYSA-N
0.000
description
1
OMIGHNLMNHATMP-UHFFFAOYSA-N
2-hydroxyethyl prop-2-enoate
Chemical compound
OCCOC(=O)C=C
OMIGHNLMNHATMP-UHFFFAOYSA-N
0.000
description
1
FDIHYONBFVCOPU-UHFFFAOYSA-N
2-methylprop-2-enoyloxymethyl benzoate
Chemical compound
CC(=C)C(=O)OCOC(=O)C1=CC=CC=C1
FDIHYONBFVCOPU-UHFFFAOYSA-N
0.000
description
1
125000003903
2-propenyl group
Chemical group
[H]C([*])([H])C([H])=C([H])[H]
0.000
description
1
125000002373
5 membered heterocyclic group
Chemical group
0.000
description
1
125000004070
6 membered heterocyclic group
Chemical group
0.000
description
1
102000009027
Albumins
Human genes
0.000
description
1
108010088751
Albumins
Proteins
0.000
description
1
206010061728
Bone lesion
Diseases
0.000
description
1
ACTFCIUTUYFGLM-UHFFFAOYSA-L
C(C)SCl.S(=O)(=O)(Cl)Cl.N(=NC(C#N)(C)C)C(C#N)(C)C.C(CCC)[N+](CCCC)(CCCC)CCCC.[OH-].C(CCC)[N+](CCCC)(CCCC)CCCC.[OH-]
Chemical compound
C(C)SCl.S(=O)(=O)(Cl)Cl.N(=NC(C#N)(C)C)C(C#N)(C)C.C(CCC)[N+](CCCC)(CCCC)CCCC.[OH-].C(CCC)[N+](CCCC)(CCCC)CCCC.[OH-]
ACTFCIUTUYFGLM-UHFFFAOYSA-L
0.000
description
1
CKUFZJLVWQLESK-UHFFFAOYSA-L
CN(C=O)C.O1CCCC1.S(=O)(=O)([O-])[O-].[Mg+2]
Chemical compound
CN(C=O)C.O1CCCC1.S(=O)(=O)([O-])[O-].[Mg+2]
CKUFZJLVWQLESK-UHFFFAOYSA-L
0.000
description
1
101100167062
Caenorhabditis elegans chch-3 gene
Proteins
0.000
description
1
OKTJSMMVPCPJKN-UHFFFAOYSA-N
Carbon
Chemical group
[C]
OKTJSMMVPCPJKN-UHFFFAOYSA-N
0.000
description
1
RWSOTUBLDIXVET-UHFFFAOYSA-N
Dihydrogen sulfide
Chemical class
S
RWSOTUBLDIXVET-UHFFFAOYSA-N
0.000
description
1
IMROMDMJAWUWLK-UHFFFAOYSA-N
Ethenol
Chemical compound
OC=C
IMROMDMJAWUWLK-UHFFFAOYSA-N
0.000
description
1
JOYRKODLDBILNP-UHFFFAOYSA-N
Ethyl urethane
Chemical compound
CCOC(N)=O
JOYRKODLDBILNP-UHFFFAOYSA-N
0.000
description
1
KMTRUDSVKNLOMY-UHFFFAOYSA-N
Ethylene carbonate
Chemical compound
O=C1OCCO1
KMTRUDSVKNLOMY-UHFFFAOYSA-N
0.000
description
1
PXGOKWXKJXAPGV-UHFFFAOYSA-N
Fluorine
Chemical compound
FF
PXGOKWXKJXAPGV-UHFFFAOYSA-N
0.000
description
1
229910052688
Gadolinium
Inorganic materials
0.000
description
1
108010010803
Gelatin
Proteins
0.000
description
1
HTTJABKRGRZYRN-UHFFFAOYSA-N
Heparin
Chemical compound
OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1
HTTJABKRGRZYRN-UHFFFAOYSA-N
0.000
description
1
WOBHKFSMXKNTIM-UHFFFAOYSA-N
Hydroxyethyl methacrylate
Chemical compound
CC(=C)C(=O)OCCO
WOBHKFSMXKNTIM-UHFFFAOYSA-N
0.000
description
1
LKDRXBCSQODPBY-AMVSKUEXSA-N
L-(-)-Sorbose
Chemical compound
OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O
LKDRXBCSQODPBY-AMVSKUEXSA-N
0.000
description
1
239000002841
Lewis acid
Substances
0.000
description
1
239000002616
MRI contrast agent
Substances
0.000
description
1
QPCDCPDFJACHGM-UHFFFAOYSA-N
N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine
Chemical compound
OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O
QPCDCPDFJACHGM-UHFFFAOYSA-N
0.000
description
1
XVJCDFXGRGHDSL-UHFFFAOYSA-N
N1(CCOCC1)C(=O)OCCl.N1(CCOCC1)C(=O)O
Chemical compound
N1(CCOCC1)C(=O)OCCl.N1(CCOCC1)C(=O)O
XVJCDFXGRGHDSL-UHFFFAOYSA-N
0.000
description
1
206010031252
Osteomyelitis
Diseases
0.000
description
1
108091005804
Peptidases
Proteins
0.000
description
1
102000035195
Peptidases
Human genes
0.000
description
1
229920002732
Polyanhydride
Polymers
0.000
description
1
239000004793
Polystyrene
Substances
0.000
description
1
YXFVVABEGXRONW-UHFFFAOYSA-N
Toluene
Natural products
CC1=CC=CC=C1
YXFVVABEGXRONW-UHFFFAOYSA-N
0.000
description
1
XJBAEMSUCWGCEM-UHFFFAOYSA-N
[chloro(phenyl)methyl] ethenyl carbonate
Chemical compound
C=COC(=O)OC(Cl)C1=CC=CC=C1
XJBAEMSUCWGCEM-UHFFFAOYSA-N
0.000
description
1
UIRNOIFHMQKWFT-UHFFFAOYSA-N
[ethenoxycarbonyloxy(phenyl)methyl] acetate
Chemical compound
C=COC(=O)OC(OC(=O)C)C1=CC=CC=C1
UIRNOIFHMQKWFT-UHFFFAOYSA-N
0.000
description
1
PDQDJZLOMGSJFK-UHFFFAOYSA-N
acetyloxymethyl 2-methylprop-2-enoate
Chemical compound
CC(=C)C(=O)OCOC(C)=O
PDQDJZLOMGSJFK-UHFFFAOYSA-N
0.000
description
1
150000003926
acrylamides
Chemical class
0.000
description
1
150000001252
acrylic acid derivatives
Chemical class
0.000
description
1
230000001476
alcoholic effect
Effects
0.000
description
1
229920003232
aliphatic polyester
Polymers
0.000
description
1
229910052783
alkali metal
Inorganic materials
0.000
description
1
125000004450
alkenylene group
Chemical group
0.000
description
1
125000002070
alkenylidene group
Chemical group
0.000
description
1
125000001118
alkylidene group
Chemical group
0.000
description
1
IYABWNGZIDDRAK-UHFFFAOYSA-N
allene
Chemical group
C=C=C
IYABWNGZIDDRAK-UHFFFAOYSA-N
0.000
description
1
230000002009
allergenic effect
Effects
0.000
description
1
125000003368
amide group
Chemical group
0.000
description
1
150000001413
amino acids
Chemical class
0.000
description
1
125000003277
amino group
Chemical group
0.000
description
1
230000003872
anastomosis
Effects
0.000
description
1
125000000129
anionic group
Chemical group
0.000
description
1
239000005557
antagonist
Substances
0.000
description
1
230000000844
anti-bacterial effect
Effects
0.000
description
1
229940088710
antibiotic agent
Drugs
0.000
description
1
229940041181
antineoplastic drug
Drugs
0.000
description
1
239000008346
aqueous phase
Substances
0.000
description
1
239000003125
aqueous solvent
Substances
0.000
description
1
125000003710
aryl alkyl group
Chemical group
0.000
description
1
239000002775
capsule
Substances
0.000
description
1
150000004649
carbonic acid derivatives
Chemical class
0.000
description
1
125000005586
carbonic acid group
Chemical group
0.000
description
1
PRNFLFIICMGARJ-UHFFFAOYSA-N
carbonochloridic acid;pyridine
Chemical compound
OC(Cl)=O.C1=CC=NC=C1
PRNFLFIICMGARJ-UHFFFAOYSA-N
0.000
description
1
MULZXZRAWSJCCF-UHFFFAOYSA-N
carbonochloridoyloxymethyl acetate
Chemical compound
CC(=O)OCOC(Cl)=O
MULZXZRAWSJCCF-UHFFFAOYSA-N
0.000
description
1
GHGHDTQEVUBIBQ-UHFFFAOYSA-N
carbonochloridoyloxymethyl benzoate
Chemical compound
ClC(=O)OCOC(=O)C1=CC=CC=C1
GHGHDTQEVUBIBQ-UHFFFAOYSA-N
0.000
description
1
WRWHFVRDUAQRIQ-UHFFFAOYSA-N
carbonothioic O,O-acid
Chemical compound
OC(O)=S
WRWHFVRDUAQRIQ-UHFFFAOYSA-N
0.000
description
1
150000007942
carboxylates
Chemical class
0.000
description
1
238000005266
casting
Methods
0.000
description
1
239000003054
catalyst
Substances
0.000
description
1
125000002091
cationic group
Chemical group
0.000
description
1
150000001805
chlorine compounds
Chemical class
0.000
description
1
FZFAMSAMCHXGEF-UHFFFAOYSA-N
chloro formate
Chemical compound
ClOC=O
FZFAMSAMCHXGEF-UHFFFAOYSA-N
0.000
description
1
CVASMYWHWRNWOX-UHFFFAOYSA-N
chloro methyl carbonate
Chemical compound
COC(=O)OCl
CVASMYWHWRNWOX-UHFFFAOYSA-N
0.000
description
1
BCUPGIHTCQJCSI-UHFFFAOYSA-N
chloromethanol
Chemical compound
OCCl
BCUPGIHTCQJCSI-UHFFFAOYSA-N
0.000
description
1
DRTIZOYLKCWDKR-UHFFFAOYSA-N
chloromethyl 1-(2-methylprop-2-enoylamino)propan-2-yl carbonate
Chemical compound
CC(=C)C(=O)NCC(C)OC(=O)OCCl
DRTIZOYLKCWDKR-UHFFFAOYSA-N
0.000
description
1
SMJYMSAPPGLBAR-UHFFFAOYSA-N
chloromethyl acetate
Chemical compound
CC(=O)OCCl
SMJYMSAPPGLBAR-UHFFFAOYSA-N
0.000
description
1
BOXZXICVMMSYPE-UHFFFAOYSA-N
chloromethyl benzoate
Chemical compound
ClCOC(=O)C1=CC=CC=C1
BOXZXICVMMSYPE-UHFFFAOYSA-N
0.000
description
1
ZKOFCURZLHKSBQ-UHFFFAOYSA-N
chloromethyl ethenyl carbonate
Chemical class
ClCOC(=O)OC=C
ZKOFCURZLHKSBQ-UHFFFAOYSA-N
0.000
description
1
JPCDQCQGUMTOBH-UHFFFAOYSA-N
chloromethyl ethylsulfanylformate
Chemical compound
CCSC(=O)OCCl
JPCDQCQGUMTOBH-UHFFFAOYSA-N
0.000
description
1
125000004218
chloromethyl group
Chemical group
[H]C([H])(Cl)*
0.000
description
1
MLXKRQZNBPENEJ-UHFFFAOYSA-N
chloromethyl hydrogen carbonate
Chemical class
OC(=O)OCCl
MLXKRQZNBPENEJ-UHFFFAOYSA-N
0.000
description
1
MFSHZGFPADYOTO-UHFFFAOYSA-N
chloromethyl methyl carbonate
Chemical compound
COC(=O)OCCl
MFSHZGFPADYOTO-UHFFFAOYSA-N
0.000
description
1
LHXLWSDJXYETLZ-UHFFFAOYSA-N
chloromethyl morpholine-4-carboxylate
Chemical compound
ClCOC(=O)N1CCOCC1
LHXLWSDJXYETLZ-UHFFFAOYSA-N
0.000
description
1
239000012568
clinical material
Substances
0.000
description
1
239000011248
coating agent
Substances
0.000
description
1
230000000052
comparative effect
Effects
0.000
description
1
238000006482
condensation reaction
Methods
0.000
description
1
229940124558
contraceptive agent
Drugs
0.000
description
1
239000003433
contraceptive agent
Substances
0.000
description
1
239000003599
detergent
Substances
0.000
description
1
150000004985
diamines
Chemical class
0.000
description
1
150000001991
dicarboxylic acids
Chemical class
0.000
description
1
125000005442
diisocyanate group
Chemical group
0.000
description
1
125000000118
dimethyl group
Chemical group
[H]C([H])([H])*
0.000
description
1
WBZKQQHYRPRKNJ-UHFFFAOYSA-L
disulfite
Chemical compound
[O-]S(=O)S([O-])(=O)=O
WBZKQQHYRPRKNJ-UHFFFAOYSA-L
0.000
description
1
239000000890
drug combination
Substances
0.000
description
1
239000002961
echo contrast media
Substances
0.000
description
1
230000002255
enzymatic effect
Effects
0.000
description
1
230000032050
esterification
Effects
0.000
description
1
238000005886
esterification reaction
Methods
0.000
description
1
PQLFROTZSIMBKR-UHFFFAOYSA-N
ethenyl carbonochloridate
Chemical compound
ClC(=O)OC=C
PQLFROTZSIMBKR-UHFFFAOYSA-N
0.000
description
1
FXPHJTKVWZVEGA-UHFFFAOYSA-N
ethenyl hydrogen carbonate
Chemical class
OC(=O)OC=C
FXPHJTKVWZVEGA-UHFFFAOYSA-N
0.000
description
1
MYXNWWDJRWCURH-UHFFFAOYSA-N
ethoxymethanethioic s-acid
Chemical compound
CCOC(S)=O
MYXNWWDJRWCURH-UHFFFAOYSA-N
0.000
description
1
230000007717
exclusion
Effects
0.000
description
1
238000001125
extrusion
Methods
0.000
description
1
238000010096
film blowing
Methods
0.000
description
1
239000011737
fluorine
Substances
0.000
description
1
229910052731
fluorine
Inorganic materials
0.000
description
1
125000002541
furyl group
Chemical group
0.000
description
1
239000000499
gel
Substances
0.000
description
1
239000008273
gelatin
Substances
0.000
description
1
229920000159
gelatin
Polymers
0.000
description
1
235000019322
gelatine
Nutrition
0.000
description
1
235000011852
gelatine desserts
Nutrition
0.000
description
1
150000004820
halides
Chemical class
0.000
description
1
229920000669
heparin
Polymers
0.000
description
1
229960002897
heparin
Drugs
0.000
description
1
238000004128
high performance liquid chromatography
Methods
0.000
description
1
239000000017
hydrogel
Substances
0.000
description
1
230000003301
hydrolyzing effect
Effects
0.000
description
1
125000004356
hydroxy functional group
Chemical group
O*
0.000
description
1
238000003384
imaging method
Methods
0.000
description
1
239000012535
impurity
Substances
0.000
description
1
238000010348
incorporation
Methods
0.000
description
1
230000002401
inhibitory effect
Effects
0.000
description
1
238000001746
injection moulding
Methods
0.000
description
1
229910052742
iron
Inorganic materials
0.000
description
1
125000001449
isopropyl group
Chemical group
[H]C([H])([H])C([H])(*)C([H])([H])[H]
0.000
description
1
235000015110
jellies
Nutrition
0.000
description
1
239000008274
jelly
Substances
0.000
description
1
150000007517
lewis acids
Chemical class
0.000
description
1
229910052943
magnesium sulfate
Inorganic materials
0.000
description
1
235000019341
magnesium sulphate
Nutrition
0.000
description
1
230000005291
magnetic effect
Effects
0.000
description
1
238000002595
magnetic resonance imaging
Methods
0.000
description
1
238000003760
magnetic stirring
Methods
0.000
description
1
239000003550
marker
Substances
0.000
description
1
238000010128
melt processing
Methods
0.000
description
1
238000002844
melting
Methods
0.000
description
1
230000008018
melting
Effects
0.000
description
1
150000002734
metacrylic acid derivatives
Chemical class
0.000
description
1
239000011859
microparticle
Substances
0.000
description
1
238000000386
microscopy
Methods
0.000
description
1
239000004005
microsphere
Substances
0.000
description
1
210000000865
mononuclear phagocyte system
Anatomy
0.000
description
1
239000002362
mulch
Substances
0.000
description
1
CZFNISFYDPIDNM-UHFFFAOYSA-N
n,n-dimethylformamide;oxolane
Chemical compound
CN(C)C=O.C1CCOC1
CZFNISFYDPIDNM-UHFFFAOYSA-N
0.000
description
1
OKPYIWASQZGASP-UHFFFAOYSA-N
n-(2-hydroxypropyl)-2-methylprop-2-enamide
Chemical compound
CC(O)CNC(=O)C(C)=C
OKPYIWASQZGASP-UHFFFAOYSA-N
0.000
description
1
GUAQVFRUPZBRJQ-UHFFFAOYSA-N
n-(3-aminopropyl)-2-methylprop-2-enamide
Chemical compound
CC(=C)C(=O)NCCCN
GUAQVFRUPZBRJQ-UHFFFAOYSA-N
0.000
description
1
125000001624
naphthyl group
Chemical group
0.000
description
1
229930014626
natural product
Natural products
0.000
description
1
230000000269
nucleophilic effect
Effects
0.000
description
1
229920001542
oligosaccharide
Polymers
0.000
description
1
150000002482
oligosaccharides
Chemical class
0.000
description
1
238000000399
optical microscopy
Methods
0.000
description
1
210000000056
organ
Anatomy
0.000
description
1
125000004043
oxo group
Chemical group
O=*
0.000
description
1
125000004430
oxygen atom
Chemical group
O*
0.000
description
1
QNGNSVIICDLXHT-UHFFFAOYSA-N
para-ethylbenzaldehyde
Natural products
CCC1=CC=C(C=O)C=C1
QNGNSVIICDLXHT-UHFFFAOYSA-N
0.000
description
1
238000007911
parenteral administration
Methods
0.000
description
1
238000003921
particle size analysis
Methods
0.000
description
1
229960003330
pentetic acid
Drugs
0.000
description
1
DDBREPKUVSBGFI-UHFFFAOYSA-N
phenobarbital
Chemical compound
C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O
DDBREPKUVSBGFI-UHFFFAOYSA-N
0.000
description
1
125000000843
phenylene group
Chemical group
C1(=C(C=CC=C1)*)*
0.000
description
1
229920001308
poly(aminoacid)
Polymers
0.000
description
1
229920001279
poly(ester amides)
Polymers
0.000
description
1
229920000747
poly(lactic acid)
Polymers
0.000
description
1
229920002463
poly(p-dioxanone) polymer
Polymers
0.000
description
1
229920002187
poly[N-2-(hydroxypropyl) methacrylamide] polymer
Polymers
0.000
description
1
229920001610
polycaprolactone
Polymers
0.000
description
1
239000004632
polycaprolactone
Substances
0.000
description
1
239000000622
polydioxanone
Substances
0.000
description
1
229920000921
polyethylene adipate
Polymers
0.000
description
1
229920000139
polyethylene terephthalate
Polymers
0.000
description
1
239000005020
polyethylene terephthalate
Substances
0.000
description
1
239000004626
polylactic acid
Substances
0.000
description
1
238000006116
polymerization reaction
Methods
0.000
description
1
229920000098
polyolefin
Polymers
0.000
description
1
229920001451
polypropylene glycol
Polymers
0.000
description
1
229920002223
polystyrene
Polymers
0.000
description
1
239000011148
porous material
Substances
0.000
description
1
235000011056
potassium acetate
Nutrition
0.000
description
1
239000004300
potassium benzoate
Substances
0.000
description
1
235000010235
potassium benzoate
Nutrition
0.000
description
1
229940103091
potassium benzoate
Drugs
0.000
description
1
235000019833
protease
Nutrition
0.000
description
1
108090000623
proteins and genes
Proteins
0.000
description
1
102000004169
proteins and genes
Human genes
0.000
description
1
125000004076
pyridyl group
Chemical group
0.000
description
1
238000001953
recrystallisation
Methods
0.000
description
1
238000001226
reprecipitation
Methods
0.000
description
1
230000004044
response
Effects
0.000
description
1
229910052701
rubidium
Inorganic materials
0.000
description
1
238000000807
solvent casting
Methods
0.000
description
1
238000000638
solvent extraction
Methods
0.000
description
1
238000009987
spinning
Methods
0.000
description
1
210000000952
spleen
Anatomy
0.000
description
1
239000003381
stabilizer
Substances
0.000
description
1
150000003431
steroids
Chemical class
0.000
description
1
238000006467
substitution reaction
Methods
0.000
description
1
239000003826
tablet
Substances
0.000
description
1
150000003512
tertiary amines
Chemical class
0.000
description
1
239000004753
textile
Substances
0.000
description
1
125000001544
thienyl group
Chemical group
0.000
description
1
210000001519
tissue
Anatomy
0.000
description
1
125000003944
tolyl group
Chemical group
0.000
description
1
231100000419
toxicity
Toxicity
0.000
description
1
230000001988
toxicity
Effects
0.000
description
1
238000002604
ultrasonography
Methods
0.000
description
1
229920002554
vinyl polymer
Polymers
0.000
description
1
238000012800
visualization
Methods
0.000
description
1
239000011592
zinc chloride
Substances
0.000
description
1
235000005074
zinc chloride
Nutrition
0.000
description
1
Classifications
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K49/00—Preparations for testing in vivo
A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K49/00—Preparations for testing in vivo
A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
Abstract
PCT No. PCT/GB93/00469 Sec. 371 Date Jan. 10, 1995 Sec. 102(e) Date Jan. 10, 1995 PCT Filed Mar. 5, 1993 PCT Pub. No. W093/18070 PCT Pub. Date Sep. 16, 1993The invention relates to non-crosslinked non-polypeptide polymers containing biodegradable lipophilic side chains incorporating methylene diester units of the formula -[-CO-O-C(R1R2)-O-CO-]-, where R1 and R2 each represents a hydrogen atom or a carbon-attached monovalent organic group or R1 and R2 together form a carbon-attached divalent organic group. The lipophilic moieties are biodegradatively cleavable to yield a water-soluble polymer.
Description
F
OPI DATE 05/10/93 AOJP DATE 09/12/93 APPLN. ID 36423/93 PCT NUMBER PCT/GB93/00469 AU9336423 INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 5 (11) International Publication Number: WO 93/18070 C08F 8/14, 20/26 A l (43) International Publication Date: 16 September 1993 (16.09.93) (21) International Application Number: PCT/GB93/00469 (74) Agent: MARSDEN, John, Christopher; Frank B. Dehn Co., Imperial House, 15-19 Kingsway, London WC2B (22) International Filing Date: 5 March 1993 (05.03.93) 6UZ (GB).
Priority data: (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, 9204918.8 6 March 1992 (06.03.92) GB DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, (71) Applicant (for all designated States except US): NYCOMED FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI pa- IMAGING AS [NO/NO]; Nycoveien 2, P.O. Box 4220 tent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, Torshov, N-0401 Oslo 4 TD, TG).
(72) Inventors; and Inventors/Applicants (for US only): KLAVENESS, Jo [NO/ Published NO]; Midtisen 5, N-1166 Oslo REDFORD, Keith With international search report.
[GB/NO]: Seljeveien 3A, N-1481 Hagan SOL- Before the expiration of the time limit for amending the BERG, Jan [NO/NO]; Syd-Fossum 43, N-1343 Eiks- claims and to be republished in the event of the receipt of marka STRANDE, Per [NO/NO]; Nordengveien amendments.
78A, N-0755 Oslo 7 (NO).
670069 (54)Title: CHEMICAL COMPOUNDS (57) Abstract Non-crosslinked non-polypeptide polymers containing biodegradable lipophilic side chains incorporating methylene diester units of the formula -[-CO-O-C(RI R 2 (where RI and R 2 each represents a hydrogen atom or a carbon-attached monovalent organic group or RI and R 2 together form a carbon-attached divalent organic group) whereby the lipophilic moieties are biodegradatively cleavable to yield a water-soluble polymer.
Ji/1 ‘WO 93/18070 PCT/GB93/00469 1 “Chemical Compounds” This invention concerns biodegradable polymers, more particularly lipophilic polymers which are biodegradable to form water-soluble polymers.
Biodegradable polymers have long been used in the medical field, for example to provide biodegradable implant materials and delayed release drug delivery systems. They are now of wider interest in overcoming the problem of pollution by long-lived insert packaging materials, household articles, detergents and the like.
There is also a need for polymers which, when they wholly or partially break down by chemical or biological means, give reliably non-toxic and readily eliminable products.
In general, biodegradation commonly involves enzymic hydrolysis of particular chemical bonds in the polymer, notably ester, urethane or amide groups which are otherwise stable in the absence of enzymes; such hydrolysis may additionaly or alternatively be effected by the presence of acids or bases. Thus, for packaging materials, aliphatic polyesters such as polycaprolactone, polyethylene adipate and polyglycolic acid are candidate materials although polyethylene terephthalate, which is very widely used in textiles and fibres, is resistant to biodegradation.
In the medical field, resorbable polymers are of interest for sutures and in wound closure, resorbable implants in the treatment of osteomyelitis and other bone lesions, tissue stapling and mesh tamponades, anastomosis Sas well as drug delivery systems and diagnostics. In these fields, polylactic acid, polyglycolic acid, poly (Llactide-co-glycolide), polydioxanone, poly (glycolide-cotrimethylene carbonate), poly (ethylene carbonate), poly (iminocarbonates), polyhydroxybutyrate, poly (amino 1- YL: .I *WO 93/18070 PCT/GB93/00469 2 acids), poly (ester-amides), poly (orthoesters) and poly (anhydrides) have all been proposed Barrows, Clinical Materials 1 (1986), pp. 233-257) as well as natural products such as polysaccharides. US-A-4180646, in particular, describes novel poly (orthoesters) for use in a very wide range of products.
In our co-pending International Patent Application No. W092/04392 the contents of which are incorporated herein by reference, we describe a broad range of polymers characterised in that they contain optionally substituted methylene diester units of the formula (I) tCO-O-C (RlR 2 -O-COt
(I)
(where R’ and R 2 each represent a hydrogen atom or a carbon-attached monovalent organic group or R 1 and R 2 together form a carbon-attached divalent organic group).
Such units are particularly rapidly degraded by common esterase enzymes but are stable in the absence of enzymes.
They may be attached not only to carbon-attached organic groups as in simple carboxylate esters but also to -0atoms as in carbonate esters.
The aforementioned units of formula are normally present in the polymer backbone, either as repeating units or as linking units between polymer sections, or are present in crosslinking groups between polymer chains. In this latter context one may, for example, convert a watersoluble long chain natural or synthetic non-biodegradable or slowly biodegradable substance, e.g. a protein such as gelatin or albumin, a polysaccharide or oligosaccharide, Sor a short chain polyacrylamide, into a water-insoluble but biodegradable form by crosslinking using crosslinking groups containing units of formula this may reduce the cost of the product in comparison with polymers which contain units of formula in the polymer backbone by reducing the relative content of the comparatively expensive units of formula i .LL WO 93/18070 PCT/GB93/00469 3 While such crosslinked polymers have a wide variety of uses as described in the above-mentioned Application No. W092/04392, their structure inevitably places some limitations on the processability of the polymers, since by virtue of their crosslinked nature they will generally be insoluble in organic as well as aqueous solvents and will not exhibit thermoplastic properties. Accordingly they cannot be subjected to conventional techniques such as solvent casting or melt processing.
The present invention is based on our finding that it is possible to prepare substantially uncrosslinked (e.g.
linear) polymers containing biodegradable lipophilic side chains incorporating methylene diester units of formula in such a way that the polymers combine the advantages of being substantially water-insoluble (or of significantly reduced water-solubility) while being thermoplastic and soluble in a variety of organic solvents and being biodegradable to give water-soluble (and therefore readily dispersible and/or eliminable) degradation products, in particular a water-soluble polymer generated by biodegradable cleavage of the lipophilic side chains.
In EP-A-0130935 there are described biodegradable esterified polypeptides of formula
-(NH-CH-CO),-
(CH) y-COO-CRaRb-OOC-R c (in which Ra and Rb are alkyl groups or hydrogen atoms and Re is an optionally substituted aliphatic or aromatic group or Rb is a hydrogen atom or an alkyl group and R 8 and Re together form a divalent group such as a dimethylene, vinylene or phenylene group, y is 1 or 2, and x is such that the molecular weight of the polymer is at least 5000) and copolymers thereof with other poly(amino acids) as delayed release carriers for drugs which may be mixed with 1 SWO 93/18070 PCT/GB93/00469 4 or enclosed by the polymer. The first step in the biodegradation of such polymers is said to be cleavage of the side chain methylene diester groups to yield polymers containing units of formula
-(NH-CH-CO)-
(CH
2 )y-COOH It is stated that such polymers will then be further degraded by peptidases to their component amino acid(s), which may be absorbed by the host to which the polymer/drug combination was administered. This pattern of degradation may be contrasted with that of the polymers of the present invention, where the polymers resulting from biodegradation of the lipophile-carrying methylene diester side chains are specifically chosen to be watersoluble so that they may be dispersed and/or eliminated without requiring further degradation.
A potential disadvantage of the polymers described in EP-A-0130935 is that the high level of hydrogen bonding exhibited by polypeptides will tend to cause them to have relatively high melting points, such that they may not be melt processable without undue degradation occurring.
Furthermore, the peptide structures may be capable of causing allergenic reactions when used in vivo.
According to one aspect of the present invention we provide biodegradable non-crosslinked polymers of low or zero water-solubilty comprising a non polypeptide polymer backbone carrying side chains, at least a proportion of i the said side chains containing lipophilic moieties bonded Sto the polymer backbone by way of methylene diester units of formula as hereinbefore defined, whereby the said lipophilic moieties are biodegradatively cleavable to yield a water-soluble polymer.
As indicated above, each of the ester groupings of the methylene diester units of formula may be either i1 WO 93/18070 PCT/GB93/00469 a carboxylate or a carbonate grouping. Polymers according to the invention may thus be represented as containing units of formula (II) fA
(II)
(O)m-CO-O-C (0)-R 3 wherein A represents a repeating unit of a non-polypeptide polymer backbone chain; L represents an optional linking group 1 is zero or m and n, which may be the same or different, are each zero or 1; R 1 and R 2 are as hereinbefore defined; and R 3 represents a lipophilic organic group.
Bio.egradation of the methylene diester groupings in polymers containing units of formula (II) will in general take place by enzymic hydrolytic cleavage of the bonds linKing the group -O-C(R’R 2 to the adjacent carbonyl groups, normally yielding an aldehyde or ketone of formula R -CO-R 2 The nature of the other degradation products’ will vary according to whether each of m and n is zero or 1; thus if m is zero a carboxyl group-containing watersoluble polymer with units of formula (III) fA
(III)
-COOH
(where A, L and 1 are as hereinbefore defined) will normally be formed, whereas if m is 1 the hypothetically formed carbonic acid group will generally eliminate carbon dioxide to yield a hydroxyl group-containing water-soluble polymer with units of formula (IV) WO 93/18070 PCT/GB93/00469 6 fA
(IV)
-OH
(where A, L and 1 are as hereinbefore defined), while products R 3 -COOH and R 3 -OH will similarly be formed depending as to whether n is zero or 1.
Factors influencing the water solubility of polymeric degradation products containing units of formula (III) or (IV) include the nature of the repeating units A and any comonomer units which may be present, the length of any linking group L, and the overall chain length of the polymer, which in general is preferably such that the molecular weight of the biodegradable polymer does not exceed about 2,000,000. Polymers with lower molecular weight may be advantageous in, for example, applications where a high level of biodegradability is required. Thus, for example, it may be preferred that polymer systems designed for use in vivo, e.g. as drug delivery systems or diagnostic aids for parenteral administration, have a molecular weight not exceeding about 40,000.
Repeating units A and any comonomer units in polymers according to the invention are preferably comparatively short, e.g. containing up to 10, e.g. 1-6 carbon atoms and optionally interrupted by one or more heteroatoms selected from oxygen, nitrogen and sulphur and/or substituted by one or more substituents comprising such heteroatoms (e.g.
as in oxo, hydroxy and amino groups). Where hydrophilic groups are included in the repeating units A and/or any comonomer units, the size of these units need not be limited and possible units thus include polyoxyethylene as in polyoxyethylene esters of methacrylic acid).
Any linking groups L are preferably of short length and include, for example, alkylene groups such as methylene, ethylene or propylene optionally terminating in and/or (where appropriate) interrupted by, for example, oxy, carbonyl, oxycarbonyl, imino or imino-carbonyl ji .1-Lf WO 93/18070 PCT/GB93/00469 7 groups. Where polar groupings such as oxygen atoms or imino groups are present the linking groups may be longer, e.g. containing up to 10 carbon atoms without unduly inhibiting water solubility. Suitable polymeric degradation products thus include, for example, polyvinyl alcohol, polyacrylic acid, polymethacrylic acid, polyhydroxyalkyl acrylates and methacrylates such as poly(2-hydroxyethyl acrylate), polysaccharides, polyesters, polyethers such as polyoxyethylenes and polyoxypropylenes, polyacrylamides and polymethacrylamides such as poly(N-hydroxyalkyl) acrylamides and methacrylamides poly N-(2-hydroxypropyl)methacrylamide), polyamides, polyurethanes and epoxy polymers.
In general the polymeric degradation products of biodegradable polymers according to the invention, by.
virtue of their water solubility, need not themselves be biodegradable; they may thus, for example, be polyolefinic. The invention therefore includes polymers containing units of formula (II) in which A is a repeating unit of a polyolefin, for example ethylene or propylene.
It will be appreciated that polymers of this type may be prepared by free radical polymerisation techniques with comparative ease and economy, in contrast with the more complex polypeptide synthesis techniques needed to prepare polymers such as those described in EP-A-0130935.
In the biodegradable polymers according to the invention at least a proportion of the repeating units should have side chain units of formula m-CO-O-C (RR 2 -0-CO- -R 3 as defined for formula (II) attached to the polymer chain; it will be appreciated that the precise level of substitution may be varied, e.g. by use of copolymerisation or partial esterification techniques as described in greater detail hereinafter, to modify as desired the solubility parameters for both the
W
II-~
)93/18070 PCr/GB93/00469 biodegradable polymer and the degradation polymer product.
R
1 and R 2 (when other than hydrogen) and R 3 in side chain units of the above formula may, for example, each be a carbon-attached hydrocarbyl or heterocyclic group, for example having 1-20 carbon atoms, e.g. an aliphatic group such as an alkyl or alkenyl group (preferably having up to carbon atoms), a cycloalkyl group (preferably having up to 10 carbon atoms), an araliphatic group such as an aralkyl group (preferably having up to 20 carbon atoms), an aryl group (preferably having up to 20 carbon atoms) or a heterocyclic group having up to 20 carbon atoms and one or more heteroatoms selected from O,S and N. Such a hydrocarbyl or heterocyclic grouping may carry one or more functional groups such as halogen atoms or groups of the formulae -NR 4
R
5
-CONR
4
RS,-OR,-SR
6 and -COOR 7 where R 4 and
R
5 which may be the same or different, are hydrogen atoms, acyl groups, or hydrocarbyl groups as defined for R 1 and
R
2
R
6 is a hydrogen atom or an acyl group or a group as defined for R 1 or R 2 and R 7 is a hydrogen atom or a group as defined for R 1 or R 2 Where R 1 and R 2 represent a divalent grouping this may, for example, be an alkylidene, alkenylidene, alkylene or alkenylene group (preferably having up to 10 carbon atoms), which may carry one or more functional groups as defined above. The carbon chains of
R
3 groups may, for example, be interrupted and/or terminated by heteroatoms such as 0, N or S.
Aliphatic groups present as, for example, R 1
R
2 or R 3 may be straight or branched, saturated or unsaturated and include, for example, alkyl and alkenyl groups, e.g.
methyl, ethyl, propyl, isopropyl, butyl, decyl or allyl groups. Araliphatic groups include (monocarbocyclic aryl)-alkyl groups, for example benzyl groups. Aryl groups include mono- or bi-cyclic aryl groups, for example phenyl, tolyl or naphthyl groups. Heterocyclic groups include 5- or 6- membered heterocyclic groups preferably having one heteroatom, for example furyl, thienyl or pyridyl groups. Halogen atom substituents may, for L i .i.i Jr. i ii 1 I- I *L I L i: li- -L L-2 ‘WO 93/18070 PCT/GB93/00469 9 example, be chlorine, bromine or iodine.
The nature and size of R 1
R
2 and R 3 will influence both the level to which polymers Dntaining units of formula (II) are rendered lipophilic and thus insolubilised with respect to water and the rate at which the side chain is biodegradably cleaved. Thus large and/or bulky groups will tend to reduce the rate of biodegradation through steric hindrance, while increasing the lipophilicity of the polymer. In one useful category of side chain R 1 and R 2 are each selected from hydrogen atoms and C 14 alkyl groups such as methyl, and R 3 represents a lower alkyl group, e.g. preferably containing 1-20 carbon atoms; such side chains combine substantial degrees of lipophilicity and biodegradability.
It will be appreciated that both the backbones and side chains of polymers according to the invention should be selected so that their degradation products are bioacceptable, in particular that they are non-toxic. In the case of polymers intended to be used for medical purposes the degradation products should also be physiologically acceptable; thus R 1
R
2
R
3 A and any linking group L should be such that the compound R’-CO-R 2 polymers containing units of formula (III) or (IV) and products of formula R 3 -COOH or R 3 -OH are physiologically acceptable and readily dispersible and eliminable, preferably all being water-soluble. Carbon dioxide liberated by cleavage of any carbonate groupings present will normally be physiologically acceptable; its generation may be functionally desirable in some u 30 applications of polymers according to the invention.
The polymers of the invention may be prepared in any Sconvenient way, for example by either reaction of a preformed water-soluble polymer with a reagent serving to introduce the desired lipophilic methylene diester side chain, or polymerisation of a functional monomer which carries the desired lipophilic methylene diester side chain.
1 WO93/18070 PCT/GB93/00469 Process may be effected by, for example, reaction of a polymer having pendant alcoholic hydroxyl’ groups polyvinyl alcohol, a polyhydroxyalkyl acrylate or a polysaccharide) with a compound of formula (V) X-CO-O-C (R’R 2
(O)-R
3
(V)
(where R 1
R
2
R
3 and n are as hereinbefore defined and X represents a leaving group such as halogen atom, e.g.
fluorine, chlorine, bromine or iodine). Reagents of formula may, for example, be prepared as described by Folkmann and Lund, Synthesis 1990, 1159. Such reactions, ‘Ach will yield polymers containing units of formula (II) which m is 1, are conveniently effected in solution, ::mple in a solvent such as tetrahydrofuran, in the -ance of a weakly nucleophilic base such as pyridine.
A catalytic amount of a tertiary amine such as 4dimethylaminopyridine may also be employed. The number of polymer hydroxyl groups which are reacted to form the desired lipophilic methylene diester groups may be controlled by appropriate choice of factors such as reagent quantities and reaction time and temperatures to affect the final hydrophilic-lipophilic balance of the lipophilised polymer. The product may be purified by standard techniques such as solvent extraction and/or dissolution/reprecipitation.
Alternatively, process may be effected by reaction of a polymer having pendant carboxyl groups (e.g.
polyacrylic acid or polymethacrylic acid) with a compound 30 of formula (VI)
X-CR’R
2 -O-CO- -R 3
(VI)
(where R’,R 2
R
3 X and n are as hereinbefore defined). Such reactions, which will yield polymers containing units of formula (II) in which m is zero, are conveniently effected in solution, for example in a solvent such as N,Ni WO 93/18070 PCT/GB93/00469 11 dimethylformamide, in the presence of a strong base, for example an alkali metal alkoxide such as potassium tbutoxide. A catalytic amount of a crown ether such as 18crown-6 may also be employed. Again the hydrophiliclipophilic balance of the polymer product can be controlled by appropriate selection of reaction parameters to determine the number of carboxyl groups which are reacted, and the product may be purified by conventional techniques.
Reagents of formula (VI) may be prepared by, for example, reaction of an aldehyde or ketone of formula R 1
CO-R
2 with an acid halide or haloformate ester of formula
R
3 -CO-X, e.g. in the presence of a catalyst’ such as zinc chloride or pyridine.
Process may also be effected by, for example, reaction of a polymer carrying functional groups such as epoxy groups with a reagent containing the .desired lipophilic methylene diester grouping and having a terminal grouping reactive with such functional groups; terminal groups reactive with epoxy groups include amino, hydroxyl and carboxy groups. Similarly, the latter groups may be present in the initial polymer and the reagent may carry a terminal epoxy group.
It is generally preferred that polymer starting materials employed in process have a molecular weight of not more than about 2,000,000.
Process may be effected using any monomers which can be polymerised or copolymerised to form noncrosslinked polymers and which possess one c- more substituents which do not participate in the polymerisation and which may be derivatised prior tI polymerisation to introduce the desired lipophilic methylene diester grouping. Free radical, condensation and ionic polymerisation techniques may be employed.
Free radical polymerisation may, for example, be effected using carboxy group-containing monomers such as acrylic acid or methacrylic acid derivatised by reaction ignature Date Tove Aas Helge Head of Patent Department and Authorised signatory WO 93/18070 PC/GB93/00469 12 with a compound of formula (VI) or by using hydroxyl group-containing monomers such as 2-hydroxyethyl acrylate or N-(2-hydroxypropyl)methacrylamide derivatised by reaction with a compou of formula Alternatively hydroxyl group-coitair ing monomers may be reacted with a compound of formula (VII) X-CO-O-C (R’R 2 -X (VII) (where R 1
,R
2 and X are as hereinbefore defined) and the resulting product reacted with an appropriate salt of a carboxylic acid R 3
-COOH.
Free radical polymerisation may also be ‘effected using vinyl carbonate esters of formula
CH
2 =CH-O-CO-O-C (RR 2
,-R
3
(VIII)
(where n, R 1
R
2 and R 3 are as defined above). Such monomers, for example having n=0, may be prepared by reaction of vinyl chloroformate with an aldehyde or ketone f:’C=O in the presence of a catalytic amount, for example, pyridine or a Lewis acid, to give an optionally substituted chloromethyl vinyl carbonate of formula (IX)
CH
2 =CH-O-‘CO-O-C (RR 2 -Cl (IX) (where R 1 and R 2 are as defined above), followed by reaction with e.g. an appropriate salt of a carboxylic acid R 3 -COOH, preferably in the presence of a catalytic 30 amount of a suitable crown ether. It will be appreciated that compounds (VIII) may formally be regarded as “vinyl alcohol” derivatised by a compound of formula (VII).
Polymers derived therefrom should accordingly be enzymatically biodegradable to polyvinyl alcohol.
Conventional bulk, solution, emulsion and suspension polymerisation techniques may be employed. The molecular weight of the polymer product, which preferably should not W0 93/18070 PCT/GB93/00469 13 exceed about 2,000,000, may be controlled by the use of chain transfer agents such as mercaptans, from which the growing polymer chain can abstract a proton leading to chain termination and formation of a sulphur radical which will initiate a new polymer chain; the molecular weight of the polymer will thus be governed by the type and concentration of the transfer agent.
Appropriate vinyl monomers, e.g. having a carbonyl group adjacent to the vinyl group, as in acrylic or methacrylic esters, for example prepared as described above, may also be subjected to ionic polymerisation techniques, both anionic and cationic; such techniques are.
particularly suited to the production of well-defined molecular weight polymer, especially comparatively low molecular weight materials.
Condensation polymerisation may be effected using a wide range of appropriately functionalised monomers, examples oi which may be represented by formulae and
(XI)
Y
(CH
2 a CH- (RR -O-CO- -R (X)
(CH
2 )b
Y
Y
(CH
2 m-CO-O-C (RR) -O-CO- -R 3
C
H2)b (XI) CH- (O)-CO-0-C (RR) -0-CO- (0)-R
(CH
2 3 i Y (where RI,R 2
,R
3 m and n are as hereinbefore defined, Y is a reactive grouping such as carboxy, hydroxyl or an epoxy group such as 2,3 epoxypropyloxy, and a, b and c may each be zero or a small integer such as 1,2 or In formula (XI) the groups R 2 and R 3 and m and n may be the same or different in the two side chains. Such monomers may be .I i i I’ /i L WO 93/18070 PCT/GB93/00469 14 employed in conventional condensation reactions with, as appropriate, reagents such as dicarboxylic acids, dialcohols, diamines, di(acid chlorides), diisocyanates and bisepoxy compounds to yield polymers such as polyesters, polyamides, polyurethanes and epoxy polymers.
The molecular weight of the polymer product may be controlled by selection of appropriate reaction times, temperatures etc and/or by use of monofunctional chain terminators.
Where appropriate, polymers according to the invention may be prepared using emulsion polymerisation techniques; this may be of particular value where, for example, it is desired to prepare the polymers in’the form of monodisperse particles. Methods of emulsion polymerisation to produce particles, especially wonodisperse particles, are described in EP-A-0003905, EP-A-0091453, EP-A-0010986 and EP-A-0106873.
Polymers according to the invention find utility in, for example, surgical implants such as sutures, soft tissue prostheses, sponges, films artificial skin) or wound dressings hydrogel sheets), flexible sheet materials and articles such as containers formed therefrom, the manufacture of biodegradable delayed release formulations for drugs or agricultural chemicals, and horticultural aids such as water-retaining “mulch” sheeting and plant containers. Such usages and the polymers shaped for use therein comprise further features of the invention. For use as prostheses, the shaped polymers may advantageously carry heparin, at least on the surface thereof.
As discussed above, the linear nature of the polymers of the invention enhances their processability. Thus by virture of their thermoplasticity they may be melt processed by standard techniques such as injection moulding, extrusion and film blowing. Solutions of the polymers in appropriate organic solvents may be used in, for example, coating of tablets, casting of films and 1 -r .n -li (iminocarzonates), polyhydroxybutyrate, poly amino
NOUN
i ‘WO 93/18070 PCT/GB93/00469 spinning of fibres.
Where a polymer of the invention is to be used as a biodegradable delayed release agent, the active material may be contained within a shell of the biodegradable polymer, e.g. in a capsule or in microspheres, or it may be physically incorporated during polymerisation so that it is uniformly distributed within the polymer and is released during biodegradation. Alternatively, the active material may comprise all or part of any of the groups R 1
R
2 or R 3 and thus be released by the enzymatic cleavage.
Typical drugs for incorporation in delayed release formulations include steroids, contraceptives, antibacterials, narcotics-antagonists and anti-tumour drugs.
The polymers of the invention, when of appropriately short chain length, may be used as plasticisers for other polymers. Where the polymers of the invention are biodegradable, degradation of the plasticiser thus either breaks up the integrity of the material or opens it up to attack by enzymes.
Biodegradable polymer particles according to the invention can also advantageously be used for diagnostic purposes. Thus an X-ray contrast agent, which will normally be a poly-iodo aromatic compound, may form all or part of the group R 3 or -C(RlR 2 so that it is liberated and safely eliminated from the body on biodegradation.
Such particles may be used for visualisation of the liver and spleen since they are trapped in the reticuloendothelial systems of those organs. The X-ray contrast agent may also be simply held physically in the polymers by being incorporated during polymerisation.
Polymer particles according to the invention may also contain paramagnetic, superparamagnetic or ferromagnetic substances which are of use in magnetic resonance imaging (MRI) diagnostics. Thus,,submicron particles of iron or a magnetic iron oxide can be physically incorporated into the polymers during polymerisation to provide iv i, I expensive units of formula 1v 17 j, WO 93/18070 PCT/GB93/00469 16 ferromagnetic or superparamagnetic particles.
Paramagnetic MRI contrast agents principally comprise paramagnetic metal ions, such as gadolinium ions, held by a chelating agent which prevents their release (and thus substantially eliminates their toxicity). Such chelating agents with complexed metal ions may be physically hel- in the polymers by being present during polymerisation or the groups R 1
R
2 and R 3 may comprise suitable chelating groups.
In general many such chelating agents are poly-amino polycarboxylic acids such as diethylene triamine pentaacetic acid Lauffer, Chem. Rev. 87 (1987), pp. 901-927).
Polymer particles of the invention may also contain uljtrasound contrast agents such as heavy materials, e.’g.
barium sulphate or iodinated compounds such as the X-ray Sontrast agents referred to above, to provide ultrasound C.-:rast media. Polymers according to the invention may also be used to prepare gas-containing porous polymer microparticles and gas-containing microballoons encapsulated by polymer coatings, both of which may be useful as ultrasound contrast agents.
The following Examples are given by way of illustvation only.
i .i i d U 11.L .t r. u .i C.LY.LIU aI .J.Isxa) S delayed release carriers for drugs which may be mixed with
NEI&_
I
1 WO 93/18070 PCT/GB93/00469
GENERAL
Methacrylic’acid was distilled under high vacuum to remove the stabiliser. 2,2′-Azobisisobutyronitrile (AIBN) thermal initiator was purified by recrystallisation from methanol.
All reactions were carried out under N 2 Size Exclusion Chromatography (SEC): Pump: Knauer HPLC pump 64 Detector: Knauer Differential refractometer Columns: Polymer Laboratores PL gels columns in series Pore sizes 104A, 500A, and 100A, particle size length 30, 30 and 60 cm respectively.
Solvent: THF Calibration: Polystyrene standards (Polymer Laboratories) Flow rate marker: Toluene Software: Polymer Laboratores GPC/SEC softwareversion 5.10 Mw: weight average molecule weight Mn: number average molecule weight Mw/Mn: polydispersity Mp: molecular weight at maximum detector response” :3 List of abbreviations Tg:
TBA-OH:
TBA:
AIBN:
SO
2 C1 2 EtSC1:
DBU:
MgSO 4
THF:
DMF:
glass transition temperature tetrabutylammonium hydroxide tetrabutylammonium 2,2’-azobisisobutyronitrile sulfuryl chloride ethanesulfenyl chloride 1,8-diazabicyclo[5.4.0]undec-7-ene(1,5-5) magnesium sulphate tetrahydrofuran N,N-dimethylformamide p uL1e mertnyi.ene dliester units of formula ()may beeithe WO093/18070 PCr/GB93/00469 18 EXAMPLE 1 Butvl methacrvlovloxvmethyl carbonate To a solution of chioromethyl chioroformate (2.84g, 22.0 mmol) and pyridine (1.78 ml, 22.0 mmol) in methylene chloride (24 ml), n-butanol (1.84 g, 20.0 mmol) was added at 0 0 C. After 30 minutes at 0*C and 21 hours at 25*C the reaction mixture was washed with aqueous hydrochloric acid (1 M, 10 ml), aqueous saturated sodium hydrogen carbonate (10 ml) and water (10 ml). The solvent was removed under reduced pressure after drying (MgSO 4 giving 2.66 g (80 of the intermediate ‘n-butyl chloromethyl carbonate as a crude product.
1 H NMR (60 MHz, CDC1 3 6:0.86 (.gH 3
-CH
2 in), 1.40 (CH 2
-CH
2 in), 4.15 (CH 2 5.63 (CH 2 -Cl, S) The intermediate n-butyl chloromethyl carbonate (2.5 g Ommol) was dissolved in dimethyl f ormamide (8 0 ml) and potassium xethacrylate (1.77 g, 15.0 mmol) was added together with a catalytic amount of 18-crown-6 (0.2 g, mmol). After 3 days at 25’C the solvent was removed under reduced pressure, cholorform (30 ml) and water (20 ml) were added and the product was extracted into chloroform. The solvent was removed under reduced pressure after drying (MgSO 4 Flash chromatography gave 1.96 g of butyl methacryloyloxymethyl carbonate.
1 HNMR (300 MHz, CHC1 3 6:0.99 (Cj 3
-CH
2 1t),l.47( IH- 2
CH
2 1.72(CHj 2
-CH
2 M) 2.01(CH 3 4.25(CH 2 5.74(H- 5.89(OCH.O s),6.27 13 CMM(75MHz,CDCl 3 )6l3.47(CH )17.97,18.71,30.36(CH 3 and CH x2) 68. 4 6(CH 0),82. 07 (0-CH 2 -)174(H=,3.5C 153.89(C=0) ,165.50(C=O).
L. k I 1 m-~imii.~ 0bi Ri 0Iii i_ ii ‘WO 93/18070 PCT/GB93/00469 19 EXAMPLE 2 a) Polymer from butyl methacryloyloxymethyl carbonate The monomer butyl methacryloyloxymethyl carbonate (350mg) was dissolved in THF (2ml). AIBN (1mg) was added as a free radical initiator. The solution was polymerised at 50″C for 5 hours. The product was recovered by precipitation into water. Size Exclusion Chromatography (SEC): Mw 165000, Mn 70000, Mw/Mn 2.3.
b) Polymer from butyl methacryloyloxymethyl carbonate A solution of butyl methacryloyloxymethyl carbonate g) in DMF was heated to 60°C and AIBN (0.005 g, 0.03 mol) was added. After 24 hours the reaction mixture was cooled and the polymer solution added dropwise to a stirred excess of methanol. The polymer was filtered and washed with methanol and water, and dried under reduced pressure.
IR (KBr): 1763 cm’ 1 ‘H NMR (300 MHz, CDC1 3 6 0.90 3H, CH 3 1.00 (m, 2H, CH 2 1.39 2H, CH 2 1.70 2H, CH 2 1.90 (m, 3H, CH 3 4.20 2H, CH 2 5.68 2H, OCH 2
O).
1 3 C NMR (75 MHz, CDC1 3 6 13.54 (CH 3
CH
2 18.73 (CH 2 30.39 (CH 2 46.26 (C-CH 3 69.72 (CH 2 83.67 153.86 175.80 Differential scanning calorimetry (DSC) indicated that onset decomposition temperature was 239.9″C (Tg was not observed). Thermal mechanical analysis indicated a glass transition temperature of 24.7*C.
Size Exclusion Chromatography (SEC): Mw=60000, Mn=29000, Mw/Mn=2.1.
oxy, carbonyl, oxycarbonyl, imino or imino-carbonyl p i m ‘WO 93/18070 PCr/GB93/00469 EXAMPLE 3 Copolymer from butyl methacrylovloxvmethyl carbonate and acrylamide The momoners butyl methacryloyloxymethyl carbonate (250mg) and acrylamide (250mg) were dissolved in THF ml). AIBN (1 mg) was added as a free radical initiator.
The solution was polymerised at 60*C for 2 hours. The product was recovered by precipitation into cold water.
EXAMPLE 4 General Procedure for chloromethyl carbonates To a solution of chloromethyl chloroformate and the stated alcohol in methylene chloride (200 ml), pyridine was added at ‘0C. After 20 min. at O’C and 21 hours at the reaction mixture was washed with aqueous hydrochloric acid (1 M, 10 ml), aqueous saturated sodium hydrogen carbonate (10 ml) and water (10 ml). The solvent was removed under reduced pressure after drying (MgSO 4 giving crude chloromethyl carbonate.
Table 1 Example Chloromethyl- Alcohol, ROH Pyridine chloroformate g, mmol g, mmol R, mmol) 4a 25.01, 194 CH, (5.64, 176) 15.52, 194 4b 15.81, 124 CH 3
CH
2 (5.20, 113) 9.91, 124 4c 20.01, 155 CH 3
(CH
2 (22.25, 12.54, 157 139) 4d 20.02, 155 PhCH 2 (15.23, 141) 12.54, 157 a) Methyl chloromethyl carbonate The compound was obtained from chloromethyl v i WO 93/18070 PC’/G B93/00469 21 chioroformate and methanol.
‘H NMR (60 MHz, CDCl 3 :6 3.98 3H, OCH 3 5.85 (s, 2H, CH 2 Cl) b) Ethyl chiorometh vi carbonate The compound was obtained from chioromethyl chioroformate and ethanol.
IH NMR (60 MHz, CDC1 3 :5 1.25 3H, CH 3 4.25 (q, 2, C 2 5.70 2H, OCH 2 Cl).
C) Decvl chloromethyl carbonate The compound was obtained from chloromethyl chloroforinate and decyl alcohol.
‘H NMR (60 MHz, CDCl 3 6 0.90-1.50 (in, 19H, CH 3 and CH 2 4.20 (mn, 2H, CH 2 5.75 2H, OCH 2 Cl) d) Benzvl chloromethyl carbonate The compound was obtained from chioromethyl chiorofornate and benzyl alcohol.
‘H NMR (60 MHz, CDCl 3 1 6 5.20 2H, PhCH 2 O,57 s 2H, ClCH 2 7.32 5H, Ph).
EXAMPLE General Procedure for methacryloy-loxymethvl carbonates Potassium tert. butoxide was added to a solution of methacrylic acid in DMF (200 til). Chioromethyl carbonate from Example 4 above was added to the 3 resulting suspension. 18-crown-6 was then added and the reaction mixture was left with stirring at room temperature for 24 hours. The reaction mixture was filtered and the solvent was removed under reduced pressure. The residue was dissolved in chloroform pyridyl groups. Halogen atom substituents may, for t WO 93/18070 PC1’/GB93/00469 22 ml) and washed with saturated aqueous sodium hydrogen carbonate (10 ml) and water (20 ml). The organic phase was dried (MgSO 4 and the solvent removed under reduced pressure.
Table 2 Example Compound, Potassium 18-crown-6 DMF mmol) methacrylate mmol) (ml) 4a, (9.67, 78) 8.71, 78 1.01, 38 350 4b, (8.04, 60) 6.73, 60 0.6, 23 300 4c, (30.61, 122) 13.67, 122 2.5, 94 600 4d, (22.01, 110) ,13.64, 110 57 j550 a) Methyl methacryloyloxinethyl carbonate The compound was obtained from methyl chioromethyl carbonate and potassium methacrylate.
IR (KBr): 1772 str.), 1737 str.), 1635 (C=C, str.) cm* 1 1 H NMR (300 MHz, CDC1.) 5 1.91 3H, CH 3 3.79 (s, 3H, CH 3 5.64 (in, 1H1, CH 2 5.80 2H, -OCH 2 6.16 (in, 1H, CH 2 13C NNR (75 MHz, CDC1 3 6 17.95 gH 3 55.13 (CH 3
O),
82.18 (-OCH 2 127.52 (CH 2 135.02 154.44 165.46 b) Ethyl methacrvlovloxinethvl carbonate The compound was obtained from ethyl chioromethyl carbonate and potassium methacrylate.
IR (KBr): 1772 str.), 1736 str.), 1635 (C-CO str.) cm*” IH NMR (300 MHz, CDC1 3 6 1.27 3H, CH 3 0 1.92 (s, chain.
‘WO93/18070 PCT/GB93/OO469 23 3H, CH 4. 23 2H, Cl-I 2 5. 66 (mn, 1H, CH 2 5.8 0 2H, -OCH 2 6.20 (mn, 1H, CH 2 1 3 C NMR (75 MHz, CDC1~) 6 15.70 CH CH 2 19.60 (gH 3
C)
72 (CH 0) 83. 05 /,-OCH 127. 76 135. 153.82 165.42 c) Decvl methacryloyloxymethyl carbonate The compound was obtained from decyl chioroinethyl carbonate and potassium methacrylate.
IR (KBr): 1772 str.), 1763 str.), 1635 str.) cmn
I
1 H NMR (300 MHz, CDC1 3 6 0. 90 3 H, Cl- 3 1. 28 (in, 14H, CH- 2 1.72 (in, 2H, CH- 2 1.99 3H, CH 3 C) 4.21 2H, CH 2 O) 57 (iHC 2 5.86 3H, -OCH 2
O)
6.24 (in, 1H, CH ‘C NMR (75 MHz, CDC1 3 6 13.78 CH 3 17.76 (CH 3
C)
22.76-31.55 (CHV) 68.60 (CHO) 81.90 (-OCH 2 127.28 134.86 153.73 165..33 d) Benzvl iethacrvloyloxvmethvl carbonate The compound was obtained from benzyl chioroinethyl carbonate and potassium inethacrylate.
IR (KBr): 3077 1772 str.), 1763 str.), 1635 str.) cm’l INMR (300 MHz, CDC1 3 6 1.96 3H, CHC),52 (s 2H, CH 2 O) 5.70 (mn, lH, CH 2 5. 87 3H, -OCH 2
O)
6. 22 (mn, 1H, CH 2 7. 39 5H, Ph).
1 3C NMR (75 MHz, CDC1 3 6 17.96 (2H 3 69.91 (CH 2
O)
82.03 (-OCH 2 127. 41 (CH 2 128. 32 (Ph) 1.34.78 153.58 165.28 A.A- formula (ii) inl wfi(.;n II ±L=P in solution, for example in a solvent such as N,N- WO 93/18070 PCT/GB93/00469 24 EXAM~PLE 6 General Procedure for Polymerization of methacryloyloxymethyl carbonates A solution of methacryloyloxymethyl carbonate (i.Og) from Example 5 above in DMF (8.0g) was heated. to and AIBN (0.005g, 0.03 mmol) was added. After 24 hours the reaction mixture was cooled and the polymer solution added dropwise to a stirred excess of methanol (nonsolvent). The polymer was filtered and washed with methanol and water, and dried under reduced pressure.
a) Polymer from methyl methacrvlovloxymethy1 carbonate ?7 TP (KBr): 1763 str.) cm” 1 NMR,11 (300 MHz, CDCl 3 6 1.00 (in, 2H, CH 2 1.90 (I, 3H), 3.85 3H, CH 3 O0) 5.70 2H, OCH 2 O) 13 C NMR (75 MHz, CDCl 3 6 46.35 (g-CH 3 56.55 (CH 3 O) I 83. 59 (-OCH 2 154. 41 175. 50 Differential scanning calorimetry (DSC) indicated that Tg=59.8’C and onset decoposition temperature was 242.2*C. Thermal mechanical analysis indicated a glass transition temperature of 59.9*C.
Size Exclusion Chromatography (SEC): Mw 100000, Mn 59000, Mw/Mn 1.7.
b) Polymer from ethyl methacrvlovloxrnethyl carbonate IR (KBr): 1763 (C 0, str.) cm’ 1 1 H NMR (300 MHz, CDCl 3 6 .00 (mn, 2H, CH 2 1.32 (t, 3 H, CH 3 1.-9 0 (in, 3 H, CH-! 3 4 .2 5 (in, 2 H, CH 2 O) 5. 70 (s, 2H, OCH O) 13C NMR (75 MHz, CDCl 3 6 15.77 (gH 3
CH
2 46.35 (C-CH- 3 65.90 (CH 0) 83.50 (-OCH 153.69 175.80 Differential scanning calorimetry (DSC) indicated that Tg=35.9*C and onset decomposition temperature was WO093/18070 PCr/G B93/00469 260.9*C. Thermal mechanical analysis indicated a glass transition temperature of 31.2*C.
Size Exclusion Chromatography (SEC): Mw 34000, Mn 20000, Mw/Mn =1.7.
c) Polymer from decvl methacrvlovloxvmethyl carbonate IR (KBr): 1763 (C 0, str.) cm’ 1 1 H NMR (300 MHz, CDCl 3 0.90 3H, CH 3 0.90 (i, 3H, CH- 2 1.30 (in, 14H, CH 2 1.70 (in, 2H, CH- 2 1.90 (I, 2H), 4.19 2H, CH 2 5.66 2H, OCH 2
O).
13 C NMR (75 MHz, CDCl 3 13.78 (CH 3 22.34-31.57
(CH-
2 46.26 (g-CH 3 68.70 (CH 2 Q) 83.67 (-OCH 2 153.55 175.80 Differential scanning calorimetry (DSC) ‘indicated that onset decomposition temperature was 232.9*C (Tg was not observed). Thermal mechanical anailysis indicated a glass transition temperature of -3.3’C.
Size Exclusion Chromatography (SEC): Mw 160000, Mn 90000, Mw/Mn 1.7.
d) Poly~er from benzyl iethacrvlov-loxvmethyl carbonate I(KBr): 3077 1763 (C 0, str.) cm’ 1 ‘H NMR (300 MHz, CDCl 3 6 0.95 (mn, 3H, CH 3 1.90 (mn, 2H) 5.25 2H, CH 0) 5.75 2H, OCH 0) 6,70 (s, Ph).
13 C NMR (75 MHz, CDCl 3 6 46.26 (-g-CH 3 68. 03 (-OCH Ph) 82.02 (-OCH 2 129.45 153.67 175.80 Differential scanning calorimetry (DSC) indicated that Tg=31.6G and oniset decomposition temperature was 197.1*C. Thermal mechanical analysis indicated a glass transition temperature of 32.8’C.
Size Exclusion Chromatography (SEC): Mw =92000, Mn 44000, Mw/Mn =2.1.
WO 93/18070 PCT/GB93/00469 26 EXAMPLE 7 Free radical solution polymerisation of benzyl methacrvloyloxymethyl carbonate giving low molecular weight polymer.
A solution of benzyl methacryloyloxymethyl carbonate 2.0 mmol) from Example 5d above in DMF (7.5 g) was heated to 60°C and allyl mercaptan (0.0015g, 0.02 mmol) together with AIBN (0.0025g, 0.015 mmol) was added. After 24 hours the reaction mixture was cooled and the polymer solution added dropwise to a stirred excess of methanol (non-solvent). The polymer was filtered and washed with methanol and water and dried under reduced pressure.
Size Exclusion Chromatography (SEC): Mw 22000, Mn 14000, Mw/Mn 1.6.
EXAMPLE 8 Free radical solution polymerisation of ethyl methacryloyloxymethyl carbonate and methacrvlic acid.
The monomer feed mixture consisting of ethyl methacryloyloxymethyl carbonate from Example 5b above and methacrylic acid in DMF (8.0g) was heated to and AIBN (0.005 g, 0.03 mol) added. After 24 hours the polymer solution was added dropwise to a stirred excess of chloroform (non-solvent), filtered and washed with more chloroform and dried under reduced pressure.
ii WO 9318070PCr/GB93/00469 ‘WO 93/18070 Table 3 Ethyl Example Methacrylic acid methacryloyloxymethyl Molar ratio mmol) carbonate methacrylic I mmol) acid: 8a 0.73, 8.48 0.25, 1.33 86:14 8b 0.73, 8.48 0.17, 0.90 90:10 8c 0.73, 8.48 0.14, 0.74 92:8 8d0.92, 10.7 0.08, 0.43 96:4 ‘H NMR (2010 MHz, CDCl 3 1. 10 6H, 2xCH 3 1.27 (t, 3H, C11 3
CH
2 1.90 4H, 2xCH 2 3.52 (bs, 1H1, OH), 4.2 (in, 2H, CH 3 CHI?) 5.72 -QCHO- Table 4: The solubility of each of the copolymners in hot and cold water, Example jSolubility (cold water) waubltr (hot Ba NoewNoer 8b None None Bc None Some Bd Complete* Complete N.B. *Complete solubilisation only after a relatively long period of time undergoing dissolution.
I
Il EXAMPLE 9 Ethyl 1-chloroethyl carbonate To a solution of 1-chioroethyl chioroforinate (23.16 g, 0.162 mol) and ethanol (7.45 g, 0.162 mol) in mnethylene chloride (200 ml), pyridine (12.82 g, 0.162 mol) was WO 93/18070 PCT/GB93/00469 28 added at 0OC. After 10 min at 0*C and 21 hours at the reaction mixture was washed with aqueous hydrochloric acid (100 ml), aqueous saturated sodium hydrogen carbonate (100 ml) and water (100 ml). The solvent was removed under reduced pressure after drying (MgSO 4 giving 18.5 g of the intermediate ethyl chloroethyl carbonate as a crude product.
1 H NMR (60 MHz, CDC1 3 6 1.30 3H, 1.85 3H,
CH
3 CH), 4.25 2H, CH 2 6.45 (q,lH, CH).
EXAMPLE Ethyl 1-methacrvloyloxvethyl carbonate 7 Potassium tert. butoxide (3.70 g, 0.033 mol) was added to a solution of methacrylic acid (2.84 g, 0.033 mol) in DMF (100 ml). Ethyl l-chloroethyl carbonate (5.08g, 0.033 mol) from Example 9 above was added to the resulting suspension. 18-crown-6 (0.61g, 2.3 mmol) was then added and the reaction mixture was left with stirring at room temperature for 3 days. The reaction mixture was filtered and the solvent was removed under reduced pressure. The residue was dissolved in chloroform (100 ml) and washed with saturated aqueous sodium hydrogen carbonate (50 ml) and water (50 ml).
The organic phase was dried (MgSO 4 and the solvent removed under reduced pressure. Flash chromatography gave 2.50g of the title product. (Adjusted for recovered starting material the yield was 1 H NMR (60 MHz, CDC1,): 6 1.30 3H, 1.60 3H,
CH
3 CH), 2.00 3H, CH 3 4.20 2H, CH2), 5.70 (m, 1H, CH 2 6.25 1H, -OCH(CH 3 6.90 1H, CH 2 (i; WO 93/18070 PCT/GB93/00469 29 EXAMPLE 11 Free radical polymerisation of ethyl 1methacryloyloxvethyl carbonate AIBN (0.033g, 0.02 mmol) was added to a solution of ethyl l-methacryloyloxyethyl carbonate (0.504g, 2.49 mmol) from Example 10 above in dry THF (8 ml) at under a dry nitrogen atmosphere. After 7 hours the reaction mixture was cooled to 20°C, and polymer iU precipitated in methanol (50 ml) and the solution filtered. The resulting polymer was dissolved in THF, reprecipitated in methanol (70 ml) and filtered, resulting in 0.138g of a white powder.
7- NMR (300 MHz, CDCl) 6 0.90 3H, 1.25 (s, 1 CH); 1.45 3H, CH 3 1.87 2H, CH 2 4.15 (bs, 2H, CHO) 6.62 (bs, 1H, -CHCH) Size Exclusion Chromatography (SEC): Mw=26500, Mn=18600, Mp=22000, Mw/Mn=1.43.
-“V’mPLE 12 Polymer from ethyl methacryloyloxymethvl carbonate, emulsion polymerisation A solution of sodium dodecyl sulphate (0.056g, 0.19 mmol) in water (20.5ml) was heated to 60″C under nitrogen atmosphere, before ethyl methacryloyloxymethyl carbonate (5.266g, 28.00 mmol) from Example 6b above was added. The polymerisation was initiated with a r 30 potassium metabisulphite (53.4 mg, 0.24 mmol)/potassium persulphate (4.38 mg, 0.02 mmol) redox system. After 16 hours at 60°C, potassium persulphate (4.38 mg, 0.02 mmol) was added, and the polymerisation was permitted to proceed for another 3 hours at 60°C and under nitrogen atmosphere before cooling to I_ I WO093/18070 PUT/C B93/00469 EXAMPLE 13 O-Acetoxymnethyl-S-ethyl carbonothioate O-Chloromethyl-s-ethyl carbonothioatel (4 .50g, 0.028 mol) in DMF (20 ml) was added to a solution of potassium acetate (2.74g, 0.028 mol) in THF (100 ml). 18-crown-6 (0.22g, 0.84 mmol) was then added and the reaction mixture was left with stirring at room temperature for 3 days. The reaction mixture was filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (silicagel, chloroform) to give 4.23g of the title product.I ‘H NMR (60 MHz, CDCl9): S 1.30 3H, CH 3
CH
2 2.20 (s, 3H-, C~H 2.95 2H, CH CHSl), 59.80 2H, OCH O).
EXAMPLE 14 AcetoxIMethyl chloroformate so C1 2 43g, 0. 018 mol) was added to 0-acetoxymethyl S ethyl carbonothioate (3.15 g, 0.018 mol) from Example 13 above at 0-5*C with stirring during 15 min. followed by stirring at room temperature for 45 min. Evaporation of EtSCl at room temperature and 11 mmHg gave a colourless liquid. Yield: 2.44g IH NMR (60 MHz, CDCl 3 S 2.20 3H, CHCO) 5.76 (s, 2H, OCH O).
Acetoxymethyl 2-methacryloyloxvethvl carbonate To a solution of acetoxymethyl chloroformate (1.00g, 0.0066 mol) and 2-hydroxyethyl methacrylate (0-86g, 0.0066 mol) in methylene chloride (30 ml), pyridine (0.52g, 0.0066 mol) was added at 0CC. After 10 min at 0*C and 18 hours at 25*C the reaction mixture was washed THF: tetrahydrofuran DMF: N,N-dimethylformamide WO093/18070 PCT/GB93/00469 31 with aqueous hydrochloric acid (100 ml), aqueous saturated sodium hydrogen carbonate (100 ml) and water (100 ml). The solvent was removed under reduced pressure after drying (MgSO 4 Flash chromatography (silicagel, hexane/ethyl acetate gave 1.05g of the title product.
IH NMR (60 MHz, CDCl 3 6 1.95 3H, CH 3 2. 10 (s, 3H, CH 3 C=O) 4.45 4H, CH 2 O) 5.55 (in, 1H, CH 2 5.75 2H, -OCH 2 6. 05 (mn, 1H, CH2=) EXAMPLE 16 N- (2-chloromethoxvcarbonloxVro~vl~methacrla-iZie To a solution of N-(2-hydroxypropyl)methacrylamide 2 (2.86g, 20 minol), and pyridine (1.90g, 24 mmol) in methylene chloride (100 ml), chloromethyl chloroformate (3.87g, 30 mmol) in methylene chloride (120 ml)ewas added at 0OC. After 15 min. at 0OC and 24 hours at the reaction mixture was washed with water (5×25 ml).
The solvent was removed under reduced pressure after drying (MgSO 4 Flash chromatography (silicagel, chloroform) gave 3.30g of the title product.
‘H NMR (60 MHz, CDCl 3 6 1.o4 2 3H, CH 3 -CH-O) 2. 0 (in, 3H, CH1 3 3. 2-4. 0 (in, 2H, NH-CH 2 -CH) 4. 8 3 (in, 1H,
CH
3 -Cj-0) 5. 6 2H, CH 2 5. 7 2H, CH 2 Cl) 6. 1-6. 7 (br s, 1H, NH).
EXAMPLE 17 a) N- (2-acetoxvmethoxvcarbonvloxvprov1l methacrylamide A THF solution (30 ml) of TBA acetate (1.21g, 4 inmol), prepared by freeze-drying an aqueous solution of equimolar TBA-OH and acetic acid, was added to a stirred solution of N- (2-chloromethoxycarbonyloxypropyl) methacrylamide (0.943g, 4 inmol) from Example 16 above in ‘WO 93/18070 PCT/GB93/00469 32 THF (10 ml) at room temperature. Following stirring for days the solvent was removed under reduced pressure and the residue was dissolved in chloroform (50 ml) and washed with water (5×10 ml). The organic phase was dried (MgSO4) and the solvent removed under reduced pressure. Flash chromatography (silicagel, hexane/ethyl acetate gave 0.486g of the title product.
IH NMR (60 MHz, CDCl 3 6 1.4 3H, CH 3 1. 0 (m, 3H, CH3C=), 2.2 3H, CH 3 3.2-4.0 2H, NH-CH 2 CH), 4.8-5.3 1H, CH3-CH-O), 5.6 2H, CH 2 5.8 2H, OCH20), 6.1-6.7 (br s, 1H, NH).
b) N- (2-acetoxymethoxycarbonyloxvpropyl)methacrylamide To a solution of N-(2-hydroxypropyl)methacrylamide 2 (0.430g, 3.0 mmol) and pyridine (0.285g, 3.6 mmol) in methylene chloride (30 ml), acetoxymethyl chloroformate from Example 14 above (0.500 g, 3.3 mmol) in methylene chloride (6 ml) was added at O’C. After 10 min. at O’C and 3 days at 25 0 C the reaction mixture was washed with water (100 ml). The solvent was removed under reduced pressure after drying (MgSO 4 Flash chromatography (silicagel, hexane/ethyl acetate gave 0.40 g of the title product.
NMR data are in good agreement with those in above.
EXAMPLE 18 Free radical polymerisation of N-(2acetoxymethoxycarbonyloxypropyl) methacrylamide AIBN (0.0138g, 0.084 mmol) was added to a solution of N- (2-acetoxymethoxycarbonyloxypropyl)methacrylamide (0.519a, 2 mmol) from Example 17 above in dry THF (8 ml) at 50*”c under a dt’y nitrogen atmosphere. After 3 days the solvent was removed under reduced pressure to give 0.439 of a white powder.
WO093/18070 PCr/GB93/00469 33 1 H NMR (200 MHz, CDC1 3 5 0. 8-1. 2 (mn, 3H, CH 3 1. 2-1. 4 (mn, 3H, CH 2 -CH (C1 3 0),1 1. 6-2. 0 (mn, 2H, CH 2 2. 1 3H,
CH
3 CO) 2.9-3.9 (mn, 2H, NH-CU 2 4.7-5.0 (mn, 1H, CH2CH (CH 3 5. 8 2H, O-CH 2 6. 2-7. 0 (mn, 1H, NH) Size Exclusion Chromatography (SEC): MW=5411, Mn=2857, Mw/Mn=1.894.
Differential scanning caloriinetry (DSC) indicated that Tg= 52.91*C.
EXAMPLE 19 N- r2- (l-chloroethoxycarbonvloxv~ ~rotvllmnethacrylainide To a solution of N-(2-hydroxypropyl)methacrylanidea (3.15g, 22 nunol) and pyridine (2.088 g, 26.4 iniol) in mnethylene chloride (100 ml), 1-chloroethyl chioroformate (4.718g, 33 minol) in methylene chloride (20 ml) was added at OOC). After 10 min. at 0’C and 5.5 hours at the reaction mixture was washed with water (5×40 ml). The solvent was removed under reduced pressure after drying (MgSO 4 to give 4.84g of the title product.
1 H NMR (60 MHz, CDCl 3 1.37 3H, C1 3 1.83 3H, CHj-CH-Cl) 1.97 (mn, 3H, CHj 3 3.3-3.6 (mn, 2H, NH-Cfl 2 4.7-5.3 (mn, 1H, CH 2
-CH(CH
3 5.3 (mn, 1H,
CH
2 5.70 (in, 1H, CH 2 6.0-6.6 (mn, 2H, NH -C1-CH-
CH
3 ~130 ‘EXAMPLE N-r2- (1-acetoxvethoxycarbonvloxv~ propyllmethacrylanide.
A THF solution (100 ml) of TBA acetate (6.93 g, 23 minol), prepared by freeze-drying an aqueous solution of equimolar TBA-OH and acetic acid, was added to a stirred solution of N-[2-(l-chloroethoxycarbonyloxy) propyl)iethacrylamide (4.736 g# 19 inmol) in THF (100 mnl) at
A
WO 93/18070 PCr/GB93/00469 34 room temperature. Following stirring for 4 days the solvent was removed under reduced pressure and the residue was’dissolved in chloroform (100 ml) and washed with water (5×20 ml). The organic phase was dried (MgsO 4 and the solvent removed under redu -td pressure.
Flash chromatography (silicagel, hexanf-, acetate gave 1.29 g of the ‘title product.
IH NMR (60 MHz, CDCl 3 6 1. 3 3H, CH 2 -CH (CH 3 1. 3H, 0-CH(Cji 3 2.0 (m,3H, CH 3 2.1 3H,
CH
3 3.3-3.6 (in, 2H, NH-Cfl 2 4.7-5.3 (in, 1H, CH 2
CH(CH
3 5.4 (in, 1H, CH 2 5.7 (mn, 1H, CH 2 6.1-6.6 (br s, 1H, NH), 6.6-6.9 (in, 1H, O-CII(CH 3 EXAMPLE 21 Free radical ipolvmerisation of N-r2-(1acetoxyethoxvcarbonvloxv) pronvlI methacrylamide.
AIBN (0.0031 g, 0.189 inmol) was added to a solution of N(2- (1-acetoxyethoxycarbonyloxpropyl)nethacrylamide (1.23 g, 4.5 minol) from Example 20 above in dry THF (18 ml) at 50*C under a dry nitrogen atmosphere. After 3 days the solvent was removed under reduced pressure.
Flash chromatography (step gradient, hexane/ethyl acetate to methanol) gave 0.96 g of a white powder.
IH NMR (200 MHz, CDC1 3 6 0.8-1.2 (in, 3H, CH 3 1.2-1.4 (in, 3H, CH 2 -CH (CHi 3 1. 5 3H, O-CH (CH 3 1. 6-2. 0 (in, 2H, CH 2 2.0-2. 2 3H, CH 3 CO) 2.9-3.9 (mn, 2H, NH-
CU
2 4.7-5.0 (in, lH, CH 2 C11(CH 3 6.2-7.0 (in, 2H, NH+O-CH (CH 3
-O)
Size Exclusion Chromatography (SEC): Mw= 1991, Mn= 1268, Mp= 2105, Mw/Mn= 1.548.
Differential scanning calorimetry (DSC) indicated that Tg= 51.53 0
C.
WO 93/18070 PCT/GB93/00469 EXAMPLE 22 Methacryloyloxymethyl benzoate Potassium tert. butoxide (10.0 g, 0.090 mol) was added to a solution of methacrylic acid (7.75 g, 0.090 mol) in DMF (300 ml). Chloromethyl benzoate 3 (15.0 g, 0.088 mol) was added to the resulting suspension. 18-crown-6 (1.8 g, 6.9 mmol) was then added and the reaction mixture was left With stirring at room temperature for 2 days. The reaction mixture was filtered and the solvent was removed under reduced pressure. The residue was dissolved in chloroform (100 ml) and washed with saturated aqueous sodium hydrogen carbonate (50 ml) and water (50 ml). The organic phase was dried (MgSO) and the solvent removed under reduced pressure. Flash chromatography gave 15.9 g of the title product.
1 H NMR (60 MHz, CDC1 3 6 2.00 3H, CH 3 5.65 (m, 1H, CH 2 6.15 2H, -OCH 2 6.35 1H, CH 2 7.50 3H, Ph), 8.05 2H, Ph).
EXAMPLE 23 Polymer from methacrvloyloxvmethvl benzoate.
A1BN (0.005 g, 0.03 mmol) was added to a solution of methacryloyloxymethyl benzoate (1.00 g, 4.55 mmol) from Example 22 above in dry THF (8 g) at 600C under a dry nitrogen atmosphere. After 24 hours the reaction mixture was cooled to 20 0 C, and the solvent removed under reduced pressure. The resulting polymer was dissolved in CH 2 C1 and reprecipitated in methanol.
Methanol was separated from the polymer by filtration, resulting in a white powder.
‘H NMR (200 MHz, CDCI 3 6 0.85 3H, CH 3 1.87 (m, 2H, CH 2 5.70 2H, -OCH20-), 7.45 3H, Ph), 8.05 2H, Ph).
Differential scanning calorimetry (DSC) indicated that
Y
‘H NMR (300 MHz, CDCl 3 6 1.27 3H, CH 3 1.92 (s, lop-, WO93/18070 PCT/GB93/00469 36 Tg=60.98°C.
Size Exclusion Chromatogrpahy (SEC): Mw= 30281, Mn=11580, Mp=32286, Mw/Mn= 2.615.
EXAMPLE 24 Methyl chloroethyl carbonate.
To a solution of chloroethyl chloroformate (35.74 g, 0.25 mol) and methanol (8.00 g, 0.25 mol) in methylene chloride (300 ml), pyridine (19.78 g, 0.25 mol) was added at O’C. After 10 min at -0C and 2 days at the reaction mixture was washed with aqueous hydrochloric acid (100 ml), aqueous saturated sodium hydrogen carbonate (100 ml) and water (100 ml). The solvent was removed under reduced pressure after drying (MgSO 4 giving 25.5 g of the intermediate methyl chloroethyl carbonate as a crude product.
‘H NMR (60 MHz, CDC1 3 6 1.85 3H, CH3CH), 3.80 (s,3H, CH 3 6.50 1H, CH).
EXAMPLE Methyl 1-methacryloyloxyethyl carbonate.
Potassium tert. butoxide (3.70 g, 0.033 mol) was added to a solution of methacrylic acid (2.84 g, 0.033 mol) in DMF (100 ml). Methyl chloroethyl carbonate (4.55 g, 0.033 mol) from Example 24 above was added to the resulting suspension. 18-crown-6 (0.61 g, 2.3 mmol) was Sthen added and the reaction mixture was left with stirring at room temperature for 3 days. The reaction mixture was filtered and the solvent was removed under reduced pressure. The residue was dissolved in chloroform (100 ml) and washed with saturated aqueous sodium hydrogen carbonate (50 ml) and water (50 ml).
The organic phase was dried (MgSO 4 and the solvent 1 ss chlrofom (00 m) ad wahedwithsatrate aqei.
WO 93/18070 PCT/GB93/00469 37 removed under reduced pressure. Flash chromatography gave 4.46 g of the title product.
‘H NMR (60 MHz, CDC1 3 1.65 3H CH3CH), 2.00 (s, 3H, CH 3 3.90 3H, CH 3 0) ,5.65 1H, CH 2 6.25 1H, CH 2 6.90 1H, CHCH 3 EXAMPLE 26 Free radical polymerisation of methyl l-methacrylovloxyethyl carbonate.
AIBN (0.005 g, 0.03 mmol) was added to a solution of methyl l-methacryloyloxyethyl carbonate (1.Og, 5.0 mmol) in dry THF (8g) at 60*C under a dry nitrogen atmosphere. After 24 hours the reaction mixture was cooled to 20’C, and the solvent removed under reduced pressure. The resulting polymer was dissolved in CH 2 C12 and roprecipitated in methanol.
Methanol was separated from the polymer by filtration, resulting in a white powder.
IH NMR (200 MHz, CDC13) 6 0.90 3H, CH3), 1.45 (s, 3H, CH3CH), 1.87 2H, CH2), 3.80 3H, CH3O), 6.65 (bs, 1H, CHCH).
Size Exclusion Chromatography (SEC): Mw= 16033, Mn= 6641, Mp= 16192, Mw/Mn= 2.41.
Differential scanning calorimetry (DSC) indicated that Tg= 57.650C.
EXAMPLE 27 Free radical emulsion homonolymerisation of benzy methacrvloyloxymethyl carbonate.
A solution of sodium dodecyl sulphate (1.6 x 10.2 mmol) in deoxygenated water (6.0 ml) was added to a 50ml two necked round bottom flask fitted with magnetic stirring bar and condenser. To the solution, potassium i_ i Y1 i .jr r _r i 1- Tg=35.9°C and onset decomposition temperature was WO93/18070 PCT/GB93/00469 38 metabisulphite (0.015 g, 6.7 x 102 mmol) dissolved in deoxygenated water (1.0 ml), and benzyl methacryloyloxymethyl carbonate (2.0 g, 8.0 mmol) were added. The reaction mixture was heated to a temperature of 60’C. To the heated reaction mixture potassium persulphate (1.25 x 10 3 g, 4.6 x 10- 3 mmol) was added and the reaction allowed to proceed. After approximately hours the polymerisation was stopped and the polymer emulsion was added dropwise to a large excess of methanol (non-solvent). The polymer was then filtered and washed with methanol and water. This procedure was repeated a total of three times in order to purify the polymer. The polymer was then collected and dried under vacuum to remove any solvent impurities. Some of the stable emulsion was not extracted as above but saved for particle size analysis by light microscopy. The size of the emulsion particles was estimated by optical microscopy and found to be just under 1m in diameter.
EXAMPLE 28 Methacryloyloxymethyl acetate Potassium tert. butoxide (5.0 g, 0.045 mol was added to a solution of methacrylic acid (3.87 g, 0.045 mol) in DMF (150 ml). Chloromethyl acetate 3 (4.86 g, 0.045 mol) was added to the resulting suspension. 18-crown-6 (0.9 g, 3.45 mmol) was then added and the reaction mixture was left with stirring at room temperature for 4 days.The reaction mixture was filtered and the solvent was removed under reduced pressure. The residue was dissolved in chloroform (100 ml) and washed with saturated aqueous sodium hydrogen carbonate (50 ml) and water (50 ml). The organic phase was dried (MgSO 4 and the solvent removed under reduced pressure. Flash chromatography gave 5.19 g (75 of the title product.
IH NMR (60 MHz, CDCl 3 6 2.00 3H, CH 3 2.18 (s, i I Y- L -I
L
WO 93/18070 PCT/GB93/00469 39 3H, CH 3 5.70 1H, CH 2 5.85 2H, -OCHO-), 6.25 1H, CH 2 EXAMPLE 29 Butyl acryloyloxymethyl carbonate Potassium tert. butoxide (5.84 g, 0.052 mol was added to a solution of acrylic acid (4.47 g, 0.045 mol) in DMF (220 ml). Butyl chloromethyl carbonate (6.5 g, 0.052 mol) in DMF (150 ml) was added to the resulting suspension. 18-crown-6 (0.6 g) was then added and the reaction mixture was left with stirring at room temperature for 2 days. The reaction mixture was filtered’ and the solvent was removed under reduced pressure. The residue was dissolved in chloroform (100 ml) and washed with saturated aqueous sodium hydrogen carbonate (50 ml) and water (50 ml). The organic phase was dried (MgSO 4 and the solvent removed under reduced pressure. Flash chromatography gave 4.57 g of the title product.
1 H NMR (60 MHz, CDC1 3 6 0.80 3H, CH3CH 2 1.28 (m, 2H, CH 2 1.60 2H, CH 2 4.15 CHgO), 5.78 2H,
OCH
2 5.88 (dd, 1H, CH 2 6.1 (dd, 1H, CH 2 6.45 (dd, 1H, CH2=CH-).
EXAMPLE Polymer from methacryloyloxymethyl acetate.
AIBN (0.005 g, 0.03 mmol) was added to a solution of Smethacryloyloxymethyl acetate (Example 28, 1.00 g, 4.55 mmol) in dry THF (8 g) at 60°C under a dry nitrogen atmosphere. After 24 hours the reaction mixture was cooled to 20*C, and the solvent removed under reduced pressure. The resulting polymer was dissolved in CH 2 C1, and reprecipitated in methanol. Methanol was separated P~ Y. L jy 1_LI 1_ -j~il i -i i WO 93/18070 PCT/IG B93/00469 from the polymer by filtration, resulting in a white powder.
Differential scanning calorimetry (DSC) indicated that Tg= 54.99°C.
Size Exclusion Chromatography (SEC): Mw= 184678, Mn= 2446, Mp=54732, Mw/Mn= 7.56 EXAMPLE 31 Polymer from ethyl 1-methacryloyloxyethyl carbonate, emulsion polymerisation A mixture of sodium dodecylsulphate (6.5 mg, 0.023 mmol) in water (2.40 ml) and potassium metabisulphite (6.3 mg, 0.028 mmol) in water (0.82 ml)was heated to 60’C under nitrogen atmosphere, before ethyl l-methacryloyloxyethyl carbonate (Example 10, 0.617 g, 3.10 mmol) was added.
The polymerisation was initiated by adding potassium persulphate (0.54 mg, 0.002 mmol) in water (0.25 ml).
The polymerisation was permitted to proceed for 20 hours at 60°C under nitrogen atmosphere, before cooling to 200C.
EXAMPLE 32 l-Chloro-l-phenylmethyl vinyl carbonate Vinyl chloroformate (3.0 g, 0.028 mol) and benzaldehyde (4.14 g. 0.039 mol) were dissolved in 1,2-dichloroethane (30 ml) and pyridine (0.1 g, 1.28 mol) was added dropwise to the stired solution. The solution was stirred for 1 day at 80*C, washed with water (25 ml), and the aqueous phase was back extracted with methylene chloride (25 ml). The combined organic phases were dried (MgSO) and concentrated to give 3.0 g (50 of the title product.
‘H NMR (60 MHz, CDC1 3 6 4.55 (dd, 1H, CH 2 4.95 (dd, il L ‘WO 93/18070 PCT/GB93/00469 41 1H, CH 2 7.05 (dd, 1H, CH 2 7.25 1H, CH-Ph), 7.40 5H, Ph).
EXAMPLE 33 1-Acetoxy-l-phenylmethyl vinyl carbonate Silver acetate (2.0 g, 0.012 mol) was added to a solution of 1-chloro-l-phenylmethyl vinyl carbonate from Example 32 (2.50 g, 0.012 mol) in DMF (60 ml). The reaction mixture was left with stirring at room temperature for 12 hours. The reaction mixture was filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (silicagel, methylene chloride) to give 0.56 g, of the title product.
1 H NMR (60 MHz, CDCl 3 6 2.24 3H, CH 3 4.60 (dd, 1H, CH 2 4.95 (dd, 1H, CH 2 7.00 (dd, 1H, 7.50 5H, Ph), 8.00 1H, -CH-Ph).
EXAMPLE 34 Free radical polymerisation of l-acetoxy-l-phenvlmethyl vinyl carbonate AIBN (0.005 g, 0.03 mol) is added to a solution of 1acetoxy-l-phenylmethyl vinyl carbonate from Example 33 g) in dry THF (8 ml) at 60’C under a dry nitrogen atmosphere. After 12 hours the solvent is removed under reduced pressure. The resulting polymer is dissolved in
CH
2 C1 2 and reprecipitated in a suitable solvent. The polymer is separated from the solvent by filtration, resulting in a white powder.
-L -i WO 93/18070 PCT/GB93/00469 42 EXAMPLE O-Benzoyloxymethyl-S-ethyl carbonothioate O-Chloromethyl-S-ethyl carbonothioate’ (5.73 g, 0.037 mol) in DMF (20 ml) was added to a solution of potassium benzoate (5.94 g, 0.037 mol), and 18-crown-6 (0.485 g, 1.85 mmol) in DMF (130 ml) was then added and the reaction mixture was left with stirring at room temperature for 24 hours. The solvent was removed under reduced pressure. The residue was dissolved in chloroform (150 ml) and washed with water (5×20 ml) and dried (MgS0 4 The solvent was removed under reduced pressure, purified by flash chromatography (silicagel, chloroform) to give 7.16 g of the-title product.
IH NMR (60 MHz, CDC1 3 6 1.3 3H, CH 3 2.9 2H,
CH
2
CH
3 6.1 2H, OCH20), 7.3-7.7 3H, Ph), 8.0-8.2 2H, Ph).
EXAMPLE 36 Benzoyloxymethyl chloroformate SO0C1 2 (4.03 g, 0.030 mol) ws added to 0benzoyloxymethyl-S-ethyl carbonothioate from Example (7.16 g, 0.030 mol) at 0-5 0 C with stirring during min. followed by stirring at room temperature for 2 hours. Evaporation of EtSCl at room temperature and 11 mmHG gave a yellow liquid. Yield: 5.30 g (83 IH NMR (60 MHz, CDC1 3 6 6.1 2H, OCH 2 7.3-7.7 (m, 3H, Ph), 8.0-8.2 2H, Ph).
i _’YL _LI rl a -1 WO093/18070 PCF/GB93/00469 43 EXAMPLE 37 N- (3-amninoprop’) methacrylamide Methacryloyl chloride (8.0 g, 0.078 mmol) in methylene chloride (10 ml) was added to a solution of 1,3diaminopropane (35 ml) in methylene chloride (200 ml) at 0*C. After 15 min. stirring at 0*C and 16 hours at the reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (silicagel, chloroform/methanol to give of the title compound.
1 H NMR (60 MHz, CDC1 3 /d 6 -aceton-) 65 1.70 (in, 2H,
CH
2
CII
2
CH
2 2. 00 3H, CH 3 C) 2. 30 2H, NH 2 2.98 (in, 2H CH NH 2 3. 35 (in, 2 H, NHCH 2 5. 35 (in, 1H, CH=) 5. 80 (in, 1H, CH 2 7. 45 (in, 1Hi, NH) EXAMPLE 38 N- (3-iethacrylamidovlipropyl’-0- (benzovloxvinethvl) carbamate Benzoyloxymethyl chlorofornate (1 equiv.) is added to a 0.1 M solution of N-(3-aminopropyl)methacrylamide (2 equiv.) in methylene chloride at 0OC. After 15 min. at 0*C and a suitable time at 25*C the reaction mixture is filtered and concentrated to dryness under reduced pressure. The residue is purified by flash chromatography giving the wanted N-(3-methacrylamidoylpropyl) -0-(benzoyloxymethyl) carbamate.
EXAMPLE 39 Free radical solution Polymerisation of N-(3methacrvlamidolpropl)-0- (benzovloxvinethvl) carbamate AIBN (3/100 equiv.) is added to a 0.5 M solution of N- (3-nethacrylamidoylpropyl) -0-(benzoyloxyinethyl) I WO 93/18070 PCT/GB93/00469 44 carbamate (1 equiv.) in THF at 60*C. After 24 hours at the reaction mixture is cooled to 25″C and concentrated to dryness under reduced pressure. SEC analysis of the crude product indicates the formation of polymer.
EXAMPLE Chloromethvl morpholine-4-carboxvlate Morpholine (1 equiv.) is slowly added to a 0.1 M solution of chloromethyl chloroformate (10 equiv.) in methylene chloride at low temperature. After 15’min at low temperature and a suitable time at 25’C the reaction mixture is filtered and concentrated to dryness under reduced pressure. The residue is purified by flash chromatography giving chloromethyl morpholine-4carboxylate.
EXAMPLE 41 Methacryloyloxvmethyl morpholine-4-carboxvlate Chloromethyl morpholine-4-carboxylate (1 equiv.) is added to a 0.1 M solution of the potassium salt of methacrylic acid (1.1 equiv.) and 18-crown-6 (2/100 equiv.) in DMF at 0OC. After 15 min at O’C and a suitable time at elevated temperature the reaction mixture is filtered and concentrated to dryness under 4 30 reduced pressure. The residue is purified by flash chromatography giving the wanted methacryloyloxymethyl morpholine-4-carboxylate.
-I1_ZL methacrylamide (0.943g, 4 mmol) from Examp±e o dLuv= ‘WO 93/18070 PCT/GB93/00469 EXAMPLE 42 Free radical polymerisation of methacryloyloxymethyl morpholine-4-carboxylate AIBN (3/100 equiv.) is added to a 0.5 M solution of methacryloyloxymethyl morpholine-4-carboxylate (1 equiv.) in THF at 60°C. After 24 hours at 60°C the reaction mixture is cooled to 25°C and concentrated to dryness under reduced pressure. Size Exclusion Chromatography (SEC) indicates formation of polymer.
EXAMPLE 43 O-Methacryloyloxymethyl-S-ethyl carbonothioate 0-Chloromethyl-S-ethyl carbonothioate 1 (1 equiv.) is added to a 0.1 M solution of the potassium salt of r;cthacrylic acid (1 equiv.) and 18-crown-6 (2/100 equiv.) in DMF at 0°C. After 15 min at O’C and a suitable time at elevated temperature the reaction mixture is filtered and concentrated to dryness under reduced pressure. The residue is purified by flash chromatography giving the wanted Qmethacryloyloxymethyl-S-ethyl carbonothioate.
EXAMPLE 44 Free radical polymerisation of 0-methacryloyloxymethyl- S-ethyl carbonothioate i AIBN (3/100 equiv.) is added to a 0.5 M solution of Qmethacryloyloxymethyl-S-ethyl carbonothioate (1 equiv.) in THF at 60°C. After 24 hours at 60°C the reaction mixture is cooled to 25 0 C and concentrated to dryness under reduced pressure. Size Exclusion Chromatography (SEC) indicates formation of polymer.
-C L 0.439 of a white powder.
WO 93/18070 PCT/GB93/00469 46 EXAMPLE Free radical solution co-polymerisation of N-(2hvdroxvpropyl)methacrylamide with N-(2-acetoxymethoxycarbonyloxypropyl)methacrylamide N-(2-hydroxypropyl)methacrylamide 2 (0.430 g, 3.0 mmol) and N-(2-acetoxymethoxycarbonyloxypropyl)methacrylamide (Example 17, 0.778 g, 3.0 mmol) were dissolved in tetrahydrofuran (10 ml) and heated to 55″C. AIBN (0.0207 g, 0.126 mmol) was added, and the mixture was stirred at 55°C for 3 days to give a clear jelly. This was dissolved in tetrahydrofuran and the solvent evaporated under reduced pressure to give a white powder (1.33 g).
Size Exclusion Chromatography (SEC) indicated formation of polymer.
EXAMPLE 46 Enzyme-catalyzed hydrolysis of polymer from methacrvloyloxymethyl benzoate mg samples of the polymer (Example 23), as finely divided powder, and 20 ml 0.9% aqueous Nacl were added to each of three reaction vials. To one of the vials was also added 0.1 ml esterase from porcine liver in 3.2 I M (NH 4 2
SO
4 (Sigma E-3128, 250U). To another of the I vials was added 0.1 ml 3.2 M (NH 4 2
SO
4 Using a pH-stat (Radiometer), the pH within each of the vials was kept 30 constant at 8.0 by adding 0.1 M NaOH. By recording the consumption of NaOH, the rates of hydrolysis were calculated. Over 45 hours at 37°C, the hydrolysis of the polymer with esterase was found to be 11 times faster than the control with (NH 4 2 SO4 without esterase.
In the control containing polymer in 0.9% NaCl no hydrolysis was found (see Fig. 1 of the accompanying drawing).
methacrylamide (4.736 g, 19 mmcl) in THF (100 ml) at WO 93/18070 PCT/GB93/00469 47 Table Consumption of 0.1 M NaOH in vial containing polymer and esterase with 0.1 ml 3.2 M in 20 ml 0.9% NaCisolution: Time (min) pH Volume 0.1 M NaOH added (ml) 0 8.00 0.000 100 8.00 0.080 220 8.00 0.142 355 8.00 0.239 2670 8.00 1.101 2710 8.00 1.105 Table 6 Consumption of 0.1 H NaOH in control containing 0.1 ml 3.2 X (NH~ 4 ),8SO. in 20 ml 0.9% NaCl-solution: Time (min) pH Volume 0.1 M NaCH added (ml) 0 8.00 0.000 120 8.00 0.012 240 8.00 0.030 4316 8.00 0.130 -fiL- I I I ml
I
WO 93/18070 WO 9318070PCF/G B93/00469 48 Table 7 Consumption of 0.1 M NaOH in control containing polymer in 20 ml 0.9% NaCl-solution: Time (min) pH Volume 0.1 M NaCH added (ml) 0 8.4 0 .115 8.0 0.002 250 8.0 0.002 300 8.0 0. 002 1600 j8.0 I0.002
REFERENCES:
1. Folkmarin Lund Synthesis 1990, 1159 2. Strohoim Kopecek Anaiew. Macromol. Chemie 1978, 109 3. Benneche Strande Wiggen Acta Chem.
Scand. 43, 1988, 74 ii
Claims (11)
1. Biodegradable non-crosslinked polymers of low or zero water-solubility comprising a non-polypeptide polymer backbone carrying side chains, at least a proportion of the said side chains containing lipophilic moieties bonded to the polymer backbone by way of methylene diester units of formula (I) tCO-O-C(R’R) -O-CO (I) (where R 1 and R 2 which may be the same or different, each represent a hydrogen atom or a carbon-attached monovalent organic group or R 1 and R 2 together form a 1F carbon-attached divalent organic group), whereby the said lipophilic moieties are biodegradatively cleavable to yield a water-soluble polymer.
2. Polymers as claimed in claim 1 containing units of formula (II) fA (II) (0)-CO-O-C (RIR) -O-CO- -R 3 (where A represents a repeating unit of a non- polypeptide polymer backbone chain; L represents a linking group; 1, m and n, which may be the same or different, are each zero or 1; R I and R 2 are as defined 30 in claim 1 and R 3 represents a lipophilic organic group).
3. Polymers as claimed in claim 2 wherien the repeating units A and any comonomer units contain 1-6 carbon atoms optionally interrupted by one or more heteroatoms selected from oxygen, nitrogen and sulphur and/or substituted by one or more substituents comprising such heteroatoms. r i, J 1 r ,r ii i 1 I -i WO 93/18070 PCT/GB93/00469
4. Polymers as claimed in claim 3 wherein A represents ethylene or propylene.
Polymers as claimed in any of claims 2 to 4 wherein L is a\ C 1 3 alkylene group optionally terminating in and/ or interrupted by one or more oxy, carbonyl, oxycarbonyl, imino or iminocarbonyl groups.
6. Polymers as claimed in any of the preceding claims which are biodegradable to yield a water-soluble polyvinyl alcohol, polyacrylic acid, polymethacrylic acid, polyhydroxyalkyl acrylate or methacrylate, polysaccharide, polyester, polyether, polyamide,’ polyurethane or epoxy polymer.
7. Polymers as claimed in any of claims 2 to 6 wherein R 1 and R 2 (when other than hydrogen) and R 3 are selected from aliphatic groups having up to 10 carbon atoms, cycloalkyl groups having up to 10 carbon atoms, araliphatic groups having up to 20 carbon atoms, aryl groups having up to 20 carbon atoms, heterocyclic groups having up to 20 carbon atoms and one or more heteroatoms selected from oxygen, sulphur and nitrogen, and any of the preceding groups carrying one or more functional substituents and/or, in the case of R 3 interrupted and/or terminated by a heteroatom selected from oxygen, nitrogen and sulphur.
8. Polymers as claimed in claim 7 wherein R I and R 2 are each selected from hydrogen atoms and C,. 4 alkyl groups and R 3 is selected from lower alkyl, phenyl and phenyl lower alkyl.
9. Polymers as claimed in any of the preceding claims in the form of surgical implants, soft tissue prostheses, sponges, films, wound dressings, flexible sheets, containers and delayed release formulations for bar and condenser. To the solution, potassium S- ‘WO 93/18070 PCT/GB93/00469 51 drugs and agricultural chemicals, particulate imaging agents or plasticisers.
A process for the preparation of a polymer as claimed in claim 1 which comprises either reaction of a preformed water-soluble polymer with a reagent serving to introduce the desired lipophilic methylene diester side chain or polymerisation of a functional monomer which carries the desired lipophilic methylene
11. A process according to of claim 10 wherein free radical polymerisation is effected. L -1 1 I MWO–
AU36423/93A
1992-03-06
1993-03-05
Chemical compounds
Ceased
AU670069B2
(en)
Applications Claiming Priority (3)
Application Number
Priority Date
Filing Date
Title
GB929204918A
GB9204918D0
(en)
1992-03-06
1992-03-06
Chemical compounds
GB9204918
1992-03-06
PCT/GB1993/000469
WO1993018070A1
(en)
1992-03-06
1993-03-05
Chemical compounds
Publications (2)
Publication Number
Publication Date
AU3642393A
AU3642393A
(en)
1993-10-05
AU670069B2
true
AU670069B2
(en)
1996-07-04
Family
ID=10711636
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU36423/93A
Ceased
AU670069B2
(en)
1992-03-06
1993-03-05
Chemical compounds
Country Status (30)
Country
Link
US
(1)
US5574097A
(en)
EP
(1)
EP0629214B1
(en)
JP
(1)
JP3281381B2
(en)
CN
(1)
CN1038940C
(en)
AT
(1)
ATE144540T1
(en)
AU
(1)
AU670069B2
(en)
BG
(1)
BG99070A
(en)
BR
(1)
BR9306043A
(en)
CA
(1)
CA2130671A1
(en)
CZ
(1)
CZ281738B6
(en)
DE
(1)
DE69305628T2
(en)
DK
(1)
DK0629214T3
(en)
ES
(1)
ES2093413T3
(en)
FI
(1)
FI944078A0
(en)
GB
(1)
GB9204918D0
(en)
GR
(1)
GR3022075T3
(en)
HU
(1)
HUT69070A
(en)
IL
(1)
IL104962A
(en)
LT
(2)
LT3216B
(en)
LV
(1)
LV10294B
(en)
MD
(2)
MD940199A
(en)
NO
(1)
NO303123B1
(en)
NZ
(1)
NZ249547A
(en)
OA
(1)
OA10097A
(en)
PH
(1)
PH30746A
(en)
PL
(1)
PL174125B1
(en)
RU
(1)
RU2114865C1
(en)
SK
(1)
SK105694A3
(en)
WO
(1)
WO1993018070A1
(en)
ZA
(2)
ZA931594B
(en)
Families Citing this family (24)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
GB9318288D0
(en)
*
1993-09-03
1993-10-20
Nycomed Imaging As
Improvements in or relating to contrast agents
GB9417941D0
(en)
*
1994-09-06
1994-10-26
Nycomed Imaging As
Improvements in or relating to contrast agents
CA2164237A1
(en)
*
1994-12-08
1996-06-09
Takeharu Tabuchi
Acrylic monomer
US6309999B1
(en)
*
1999-03-19
2001-10-30
Chandra P. Sharma
Process for the preparation of an immunoadsorbent matrix
US6720445B2
(en)
*
2000-12-21
2004-04-13
Beacon Laboratories, Inc.
Acetyloxymethyl esters and methods for using the same
HU0400183A2
(en)
2001-06-11
2004-07-28
Xenoport Inc.
Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
US8048917B2
(en)
2005-04-06
2011-11-01
Xenoport, Inc.
Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2
(en)
2001-06-11
2004-11-16
Xenoport, Inc.
Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2
(en)
2001-06-11
2007-03-06
Xenoport, Inc.
Prodrugs of GABA analogs, compositions and uses thereof
AUPR951501A0
(en)
*
2001-12-14
2002-01-24
Smart Drug Systems Inc
Modified sustained release pharmaceutical system
US8313760B2
(en)
2002-05-24
2012-11-20
Angiotech International Ag
Compositions and methods for coating medical implants
BR0311285A
(en)
2002-05-24
2007-04-27
Angiotech Int Ag
medical implant coating compositions and processes
US20030235610A1
(en)
*
2002-06-21
2003-12-25
Piedmont Pharmaceuticals, Llc
Liposomes containing biologically active compounds
AU2004293030A1
(en)
*
2003-11-20
2005-06-09
Angiotech International Ag
Electrical devices and anti-scarring agents
BRPI0517227B8
(en)
2004-11-04
2021-05-25
Xenoport Inc
1-{[alpha-isobutanoyloxyethoxy)carbonyl]amino methyl}-1-acetic acid extended-release tablet, and use of the tablet
AU2005100176A4
(en)
*
2005-03-01
2005-04-07
Gym Tv Pty Ltd
Garbage bin clip
US8999323B2
(en)
2007-11-23
2015-04-07
Technische Universität Wien
Composition that can be cured by polymerisation for the production of biodegradable, biocompatible, cross-linkable polymers on the basis of polyvinyl alcohol
RU2541534C2
(en)
*
2010-06-17
2015-02-20
Басф Се
Polymers with carbohydrate side groups and use thereof
RU2543895C2
(en)
*
2013-05-17
2015-03-10
Общество С Ограниченной Ответственностью “Научно-Производственный Центр “Амфион”
Hydrogel material based on cross-linked polyvinyl alcohol
JP7115914B2
(en)
2017-06-23
2022-08-09
住友化学株式会社
RESIST COMPOSITION AND RESIST PATTERN MANUFACTURING METHOD
GB201810788D0
(en)
*
2018-06-29
2018-08-15
Biocompatibles Uk Ltd
Biodegradable polymer
RU2687231C1
(en)
*
2018-08-03
2019-05-08
Сергей Борисович Врублевский
Method of producing pigments
CN109928879A
(en)
*
2019-03-05
2019-06-25
贵州大学
A kind of acrylate carbonic ester and its homopolymer and copolymer material
CN111892707B
(en)
*
2020-06-18
2021-08-13
中山大学
Cationic polyamide material and preparation method and application thereof
Family Cites Families (11)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US4180646A
(en)
1975-01-28
1979-12-25
Alza Corporation
Novel orthoester polymers and orthocarbonate polymers
US4356166A
(en)
*
1978-12-08
1982-10-26
University Of Utah
Time-release chemical delivery system
US4276885A
(en)
1979-05-04
1981-07-07
Rasor Associates, Inc
Ultrasonic image enhancement
US4718433A
(en)
1983-01-27
1988-01-12
Feinstein Steven B
Contrast agents for ultrasonic imaging
EP0130935B1
(en)
*
1983-07-01
1987-04-15
Battelle Memorial Institute
Biodegradable polypeptide and its use in the sustained release of medicaments
US4741956A
(en)
*
1986-07-09
1988-05-03
Exxon Research And Engineering Company
Biodegradable coatings of ionomer polymer
IE66912B1
(en)
1988-02-05
1996-02-07
Schering Ag
Ultrasonic contrast agents process for their preparation and their use as diagnostic and therapeutic agents
GB9003821D0
(en)
1990-02-20
1990-04-18
Danbiosyst Uk
Diagnostic aid
US5137928A
(en)
1990-04-26
1992-08-11
Hoechst Aktiengesellschaft
Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2
(en)
1990-05-18
1993-04-29
Bracco International B.V.
Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
PH31064A
(en)
1990-09-07
1998-02-05
Nycomed As Of Nycoveten
Polymers containing diester units.
1992
1992-03-06
GB
GB929204918A
patent/GB9204918D0/en
active
Pending
1993
1993-03-05
CN
CN93104053A
patent/CN1038940C/en
not_active
Expired – Fee Related
1993-03-05
RU
RU94045151A
patent/RU2114865C1/en
active
1993-03-05
AT
AT93905526T
patent/ATE144540T1/en
not_active
IP Right Cessation
1993-03-05
PL
PL93305024A
patent/PL174125B1/en
unknown
1993-03-05
JP
JP51546393A
patent/JP3281381B2/en
not_active
Expired – Fee Related
1993-03-05
CA
CA002130671A
patent/CA2130671A1/en
not_active
Abandoned
1993-03-05
US
US08/290,875
patent/US5574097A/en
not_active
Expired – Fee Related
1993-03-05
DK
DK93905526.5T
patent/DK0629214T3/en
active
1993-03-05
LT
LTIP391A
patent/LT3216B/en
not_active
IP Right Cessation
1993-03-05
LT
LTIP388A
patent/LT3199B/en
not_active
IP Right Cessation
1993-03-05
NZ
NZ249547A
patent/NZ249547A/en
unknown
1993-03-05
ZA
ZA931594A
patent/ZA931594B/en
unknown
1993-03-05
CZ
CZ942152A
patent/CZ281738B6/en
unknown
1993-03-05
AU
AU36423/93A
patent/AU670069B2/en
not_active
Ceased
1993-03-05
ZA
ZA931599A
patent/ZA931599B/en
unknown
1993-03-05
WO
PCT/GB1993/000469
patent/WO1993018070A1/en
active
IP Right Grant
1993-03-05
HU
HU9402563A
patent/HUT69070A/en
unknown
1993-03-05
LV
LVP-93-170A
patent/LV10294B/en
unknown
1993-03-05
SK
SK1056-94A
patent/SK105694A3/en
unknown
1993-03-05
BR
BR9306043A
patent/BR9306043A/en
not_active
Application Discontinuation
1993-03-05
ES
ES93905526T
patent/ES2093413T3/en
not_active
Expired – Lifetime
1993-03-05
EP
EP93905526A
patent/EP0629214B1/en
not_active
Expired – Lifetime
1993-03-05
DE
DE69305628T
patent/DE69305628T2/en
not_active
Expired – Fee Related
1993-03-05
IL
IL10496293A
patent/IL104962A/en
not_active
IP Right Cessation
1993-03-08
PH
PH45821A
patent/PH30746A/en
unknown
1994
1994-07-11
MD
MD94-0199A
patent/MD940199A/en
unknown
1994-07-14
MD
MD94-0206A
patent/MD940206A/en
unknown
1994-08-24
OA
OA60557A
patent/OA10097A/en
unknown
1994-09-05
FI
FI944078A
patent/FI944078A0/en
unknown
1994-09-05
NO
NO943273A
patent/NO303123B1/en
not_active
IP Right Cessation
1994-09-28
BG
BG99070A
patent/BG99070A/en
unknown
1996
1996-12-18
GR
GR960403520T
patent/GR3022075T3/en
unknown
Also Published As
Publication number
Publication date
NO303123B1
(en)
1998-06-02
MD940199A
(en)
1996-01-31
JPH07505177A
(en)
1995-06-08
NO943273L
(en)
1994-09-05
HUT69070A
(en)
1995-08-28
RU94045151A
(en)
1996-09-27
EP0629214A1
(en)
1994-12-21
CZ281738B6
(en)
1997-01-15
NO943273D0
(en)
1994-09-05
GR3022075T3
(en)
1997-03-31
SK105694A3
(en)
1995-04-12
FI944078A
(en)
1994-09-05
LTIP388A
(en)
1994-09-25
EP0629214B1
(en)
1996-10-23
CN1084524A
(en)
1994-03-30
DK0629214T3
(en)
1996-11-18
ZA931594B
(en)
1993-09-27
ES2093413T3
(en)
1996-12-16
NZ249547A
(en)
1996-08-27
LTIP391A
(en)
1994-09-25
BR9306043A
(en)
1997-11-18
FI944078A0
(en)
1994-09-05
PH30746A
(en)
1997-10-17
LV10294A
(en)
1994-10-20
IL104962A
(en)
1996-01-31
CA2130671A1
(en)
1993-09-07
ZA931599B
(en)
1993-12-28
DE69305628D1
(en)
1996-11-28
IL104962A0
(en)
1993-07-08
LT3199B
(en)
1995-03-27
MD940206A
(en)
1996-01-31
HU9402563D0
(en)
1994-11-28
GB9204918D0
(en)
1992-04-22
CN1038940C
(en)
1998-07-01
RU2114865C1
(en)
1998-07-10
DE69305628T2
(en)
1997-03-06
AU3642393A
(en)
1993-10-05
OA10097A
(en)
1996-12-18
LV10294B
(en)
1995-12-20
ATE144540T1
(en)
1996-11-15
JP3281381B2
(en)
2002-05-13
CZ215294A3
(en)
1995-08-16
WO1993018070A1
(en)
1993-09-16
BG99070A
(en)
1995-08-28
LT3216B
(en)
1995-04-25
PL174125B1
(en)
1998-06-30
US5574097A
(en)
1996-11-12
Similar Documents
Publication
Publication Date
Title
AU670069B2
(en)
1996-07-04
Chemical compounds
US5674468A
(en)
1997-10-07
Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
AU676467B2
(en)
1997-03-13
Improvements in or relating to contrast agents
JP3161728B2
(en)
2001-04-25
Biodegradable polymer
JP4411355B2
(en)
2010-02-10
Monomers derived from hydroxy acids and polymers prepared therefrom
KR0148704B1
(en)
1998-08-17
Biodegradable polymer as drug delivery
US9295734B2
(en)
2016-03-29
Branched amphipathic block polymer and molecular aggregate and drug delivery system using same
CN107915832B
(en)
2020-07-28
X-ray developed iodine-containing polycarbonate/polyester material and preparation method and application thereof
US9006349B2
(en)
2015-04-14
Temperature-sensitive polyethylene glycol / polyester block copolymer in which bioactive functional group is introduced into side chain thereof
LT3665B
(en)
1996-01-25
Polymers containing diester units
None